

Population estimates of biomarkers of exposure to carbon monoxide, nicotine, and NNK in smokers and non-smokers

Felix Ayala-Fierro¹, Thomas Verron², Pavel Lizhnyak³, Robert Freeland⁴, Kimberly Frost-Pineda⁴, Ashraf Elamin⁵, Gaddamanugu Prasad⁴, Mohamadi Sarkar³

1 JUUL Labs

2 SEITA - Imperial Brands

3 Altria

4 Reynolds American

5 Philip Morris International

Funding: Not applicable.

Potential competing interests: This publication represents the Biomarker Subgroup of CORESTA. All authors are employees of the tobacco industry.

Abstract

Assessment of potentially reduced risk tobacco products (PRRPs) can be facilitated with availability of a single baseline population estimate for biomarkers of exposure (BOEs) for select constituents in cigarette smoke. The purpose of this analysis is to establish such a population estimate for BOEs to carbon monoxide (carboxyhemoglobin - COHb), nicotine (Nicotine Equivalents - NEQ), and nicotine-derived nitrosamine ketone (NNK; total urinary 4-[methylnitrosamino]-1-[3-pyridyl]-1-butanol [NNAL] - NNAL) based on pooled weighted average from published literature. Four databases - PubMed®, ScienceDirect®, TOXNET®, and Google Scholar™ – were systematically searched for published literature between 2008-2020 based on a protocol for literature assessment to identify and select studies. A total of 217 scientific articles were identified and reviewed for potential inclusion, 87 studies met the pre-set criteria (reported clinical studies and/or observational studies with reportable original values), and 53 studies met the inclusion criteria for each BOE. We determined the pooled weighted average based on Epanechnikov kernel density curves. The NNAL levels were normalized to a unit (pmol/mg creatinine) commonly used in research studies and reported as geometric means. Smokers had significantly ($p < 0.05$) higher levels of NNAL (1.112 pmol/mg creatinine; 95% confidence interval [CI] 0.161, 2.047), COHb (5.21 % saturation; 95% CI 3.91, 6.00), and NEQ (13.81 mg/24 h; 95% CI 9.08, 21.19) compared to non-smokers (0.008 pmol/mg creatinine, 95% CI 0.001, 0.017 for NNAL; 1.05% saturation, 95% CI 0.04, 2.07 for COHb; and 0.058 mg/24 h, 95% CI 0.016, 0.112 for NEQ). This research addresses the existing gap in lack of population level estimates for BOEs by establishing population level estimates for COHb, NEQ, and NNAL that can be used to determine changes in exposure for smokers switching to PRRPs.

Definitions

Clinical Trial

Defined by National Institutes of Health (NIH)

Observational Studies

Defined by National Institute of Dental and Craniofacial Research (NIDCR)

Corresponding author: Mohamadi A. Sarkar (Mohamadi.A.Sarkar@altria.com). Altria Client Services LLC, Richmond, VA, USA.

Keywords: Potentially reduced risk tobacco products, biomarker levels, carboxyhemoglobin, nicotine equivalents, NNAL, population estimates.

Funding Details: Not applicable.

Disclosure Statement: This publication represents the Biomarker Subgroup of CORESTA. All authors are employees of the tobacco industry.

Introduction

Cigarettes are the most harmful tobacco products, and adult smokers who are unable or unwilling to quit may benefit by switching to potentially reduced risk tobacco products (PRRPs). In recent years, the tobacco product landscape has changed dramatically with the introduction of non-combustible products (e.g., e-vapor, heated tobacco products, and oral tobacco derived nicotine products) that deliver nicotine without many of the harmful and potentially harmful constituents (HPHCs) associated with combustion and are therefore potentially less deleterious than cigarettes. Biomarkers of exposure (BOEs) to HPHCs inform the potential health risks from PRRPs as actually used by adult tobacco consumers. Establishing population level estimates of exposure among smokers and non-smokers can help determine changes in exposure from using a PRRP relative to cigarettes. Most clinical studies determine the impact of switching to a PRRP by either comparing to the baseline level of exposure among the study participants that switched or comparing to a control group that continues to smoke. The availability of a single, reliable, weighted-average estimate of BOEs can be useful in determining the relative changes in exposure in adult smokers switching to PRRPs at the population level.

While biomarkers of tobacco exposure can be measured in many different biological matrices, most are measured through the collection of blood or urine samples (Liveri, Liang, & Sarkar, 2020; Sarkar et al., 2010). Historically, urinary or salivary cotinine have been the most common measure of nicotine exposure, but recent studies often report urinary total nicotine equivalents (NEQ) that can be measured in either urine collected over 24 hours or assessed from a spot-urine sample and are often creatinine adjusted (Sarkar et al., 2013). One of the challenges for comparison of levels for the same BOE across studies is the lack of standardization of units for the reporting of results. For example, Appleton et al.'s 2014 review found nine different units of 4-[methylnitrosamino]-1-[3-pyridyl]-1-butanol (NNAL) expression reported in the literature (Appleton, Olegario, & Lipowicz, 2014). At the population level, no reliable estimates of BOEs have been harmonized to a common unit of measurement. Given the wide and growing range of nicotine products, from heated tobacco products and e-cigarettes to snus and modern oral tobacco-derived nicotine products, developing standardized estimates of carboxyhemoglobin (COHb), NEQ, and NNAL will enable researchers to quantify the relative effects across these diverse products and equally diverse use patterns.

Assessment of biomarkers for cigarette smoke constituents must be specific and not from other sources of exposure, as well as representative of the particulate phase and gas/vapor phase of cigarette smoke. Total urinary NNAL represents metabolites of a tobacco-specific nitrosamine (TSNA), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNK, nicotine-derived nitrosamine ketone), which is found in the particulate-phase of the smoke aerosol and identified as a carcinogen (U.S. Food and Drug Administration, 2012). Since NNK is tobacco-specific, this biomarker differentiates between smokers and non-smokers (Roethig et al., 2009); correlates with cigarette consumption (Hecht, 2004); and provides a reasonable proxy for overall smoke exposure (Wang, Liang, Mendes, & Sarkar, 2011). Due to its long half-life (> 10 days), NNAL levels are not prone to the variability in measurement due to transient changes in smoking behavior (Goniewicz et al., 2009; Hecht et al.,

1999). Exposure to nicotine provides a direct assessment of cigarette smoking as nicotine is rapidly metabolized to several metabolites that reflect ~80-90% of the daily nicotine uptake (Feng et al., 2007; Hatsukami, Benowitz, Rennard, Oncken, & Hecht, 2006; Kandel, Hu, Schaffran, Udry, & Benowitz, 2007; St Charles, Krautter, Dixon, & Mariner, 2006). The molar sum of nicotine and its five major metabolites, expressed as NEQ, provides an accurate assessment of total nicotine exposure. Exposure to carbon monoxide (CO) as a combustion product found in the gas phase of cigarette smoke can most accurately be measured as a percent of hemoglobin saturation (COHb) and helps differentiate between smokers and non-smokers (Hatsukami et al., 2007; Rodgman & Perfetti, 2009; Stratton, Shetty, Wallace, & Bondurant, 2001). Furthermore, COHb has been suggested as a biomarker of cardiovascular risk in never smokers (Hedblad, Engström, Janzon, Berglund, & Janzon, 2006). Thus, total NNAL, NEQ, and COHb provide a reasonably accurate and specific assessment of overall cigarette smoke exposure.

The aim of this analysis is to estimate a population level weighted average of total NNAL, NEQ, and COHb in smokers and non-smokers that can be used as a baseline for the comparison of changes in exposure for smokers switching to PRRPs. This analysis is based on a review of the published literature from 2008 through 2020. We estimate a single pooled weighted average representative of the population level exposure. A pooling of weighted observed values is an important statistical methodology that provides the opportunity to combine results of studies, allowing an increase in the number of observations and to improve estimates of the effect size across a diverse set of study participants that can reasonably represent the population (Hunter & Schmidt, 1990; Schmidt & Hunter, 2004).

This analysis was initiated by scientists from five global tobacco companies involved in the Cooperation Centre for Scientific Research Relative to Tobacco (CORESTA) Biomarker Sub-Group (BMSG). Founded in 1956 under French law and consisting of 158 member organizations across 37 countries, CORESTA is a non-profit organization whose mission is to promote international cooperation in scientific research relative to tobacco and its derived products. CORESTA seeks to develop standardized nomenclature, definitions, and methodologies as well as provide guidelines, reports, and training across four research domains: agronomy and leaf integrity, phytopathology and genetics, product technology, and smoke science. One of the objectives of the BMSG is to review present knowledge of tobacco and smoking related BOEs and effects. We share the findings from our pooling of weighted average-observed values in this manuscript.

Methods

The literature review was conducted based on inclusion criteria developed (described in Supplemental Appendix A), to determine eligibility of the studies and to ensure relevance. We defined the clinical and observations studies as follows: **Clinical Study**: A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. (<https://grants.nih.gov/policy/clinical-trials/definition.htm>).

Observational Study: A research study in which observations are recorded and data analyzed without administration of an intervention or alteration of the care people receive. (<https://www.nidcr.nih.gov/research/human-subjects-research/types-of-human-subjects-research>).

The major components of the inclusion criteria were: timeframe (2008-2020); publication type (e.g., relevance, country); study design (e.g., crossover/randomized controlled clinical study, sample size); analyte (e.g., biomarker analyzed, analytical method, biological fluid measurement); and demographics (e.g., gender, age, smoking history). The default publication language was English, and all studies included human subjects. Four databases (PubMed®, ScienceDirect®, TOXNET®, and Google Scholar™) were queried for each search to represent relevant publications in the field of cigarette smoking. The literature search strategy consisted of a core of three terms, "clinical studies," "observational studies," and "cigarette smoking," in conjunction with the specific BOEs of interest, COHb, NEQs, and NNAL, published worldwide between 2008 and 2020. An evidence table created based on the studies that met the inclusion criteria was processed by reviewing and filtering data by publication year, group (e.g., smokers), source of data, source of the publication (e.g., academia), and reported statistical parameters (e.g., mean, standard deviation, etc.). Finally, data analysis was separately conducted for each biomarker. For NNAL, a conversion table was developed based on two key assumptions: a median creatinine level of 122.665 mg/dL (Barr et al., 2005) equivalent to 2,208 mg creatinine/24 h (>20 years old adults) and an assumed urine volume of 1,800 mL excreted per day (Clark et al., 2011). The NNAL molecular weight of 209.24 g/mol was used to convert picogram levels to picomol levels.

Statistical Analysis

The database was organized by categories, filtered, and data-weighted according to the size of the groups. We pooled the aggregated data from different studies, taking into account the smoking status after weighting the studies by sample size. For each group, the density of the data was estimated using a kernel density estimator approach. In this study, the Epanechnikov kernel (Epanechnikov, 1969), has been used:

$$Epanechnikov: K(x) = \frac{3}{4} \{ \max(1 - x^2; 0) \} \quad (\text{Equation 1})$$

Based on this density curve, the key statistical information such as the average, the standard deviation, and confidence interval (CI) have been estimated. A general linear model with Tukey's all-pair comparisons was used to compare the average biomarker levels obtained by group.

Results

Literature Search

A total of 195 publications were originally identified for this analysis. Four reviewers assessed the publications independently and excluded 111 publications. The following reasons for exclusion were documented in the evidence table: data reported in other than humans, no clinical or observation data reported, studies that constituted reviews with no original data, or the data was part of another publication. In addition, NNAL studies were excluded when data format (e.g., arithmetic means or median values) could not be converted to the unit of choice for the analysis. Overall, 84 publications were found to meet the initial criteria for inclusion (Table 1).

Table 1. Total scientific studies

Biomarker	Number of Publications		
	Total	Met Criteria	Pooling Analysis Inclusion
COHb	50	31	21
NEQs	69	11	10
NNAL	76	42	19
Total	195	84	50

COHb: Carboxyhemoglobin; NEQ: Nicotine Equivalents; NNAL: total urinary 4-[methylnitrosamino]-1-[3-pyridyl]-1-butanol

After a careful review of the reported analytical data, 50 published cross-sectional clinical or observational studies reporting biomarker data were included in the analysis. The relevant data were captured in an evidence table according to gender, race, age, and other demographics and grouped by smokers, non-smokers, and former smokers (Supplemental Appendix A). The rationale for data exclusion was documented.

Characteristics of the Included Studies

The main characteristics of the included studies are shown in the evidence table (Supplemental Appendix A). The studies included adult smokers from a diverse range of geographical regions, including USA, Brazil, Switzerland, Poland, Korea, Taiwan, Japan, South Africa, and Nepal for COHb; USA, Germany, UK and Japan for NEQ; and USA, Canada, Poland, Germany, Syria, Egypt, and China for NNAL.

A total of 33,882 smokers were included in the analysis with 3,238 non-smokers as control subjects. A total of 16,311 smokers, 278 former smokers, and 1,949 non-smokers were included in the COHb analysis from 14 clinical studies (Appleton, Liu, Lipowicz, & Sarkar, 2015; Haziza, de La Bourdonnaye, Merlet, et al., 2016; Haziza, de La Bourdonnaye, Skiada, et al., 2016; Haziza et al., 2017; Lüdicke, Baker, Magnette, Picavet, & Weitkunat, 2017; Lüdicke, Haziza, Weitkunat, & Magnette, 2016; Lüdicke et al., 2018; Round, Chen, Taylor, & Schmidt, 2018; Sarkar et al., 2010; Tran, Bosilkovska, de La Bourdonnaye, Blanc, & Haziza, 2020; Tricker, Jang, Martin Leroy, Lindner, & Dempsey, 2012; Tricker, Kanada, et al., 2012; Tricker, Stewart, et al., 2012; Unverdorben et al., 2010; van Staden, Groenewald, Engelbrecht, Becker, & Hazelhurst, 2013) and 7 observational studies (Kung, Wang, & Tseng, 2008; Mendes et al., 2009; Muhammad-Kah, Hayden, Liang, Frost-Pineda, & Sarkar, 2011; Oliveri et al., 2020; Rodgman & Perfetti, 2009; Theron, Schultz, Ker, & Falzone, 2010; Wang et al., 2010). A total of 5,353 smokers, 55 former smokers, and 129 non-smokers were included in the NEQ analysis from 8 clinical studies (D'Ruiz, Graff, & Robinson, 2016; Lowe, Gregg, & McEwan, 2009; Morin, Shepperd, Eldridge, Poirier, & Voisine, 2011; Prasad, Jones, Chen, & Gregg, 2016; Roethig et al., 2008; Round et al., 2018; Scherer, Newland, Papadopolou, & Minet, 2014; Yuki, Takeshige, Nakaya, & Futamura, 2018) and 2 observational studies (Camacho, Sommarström, Prasad, & Cunningham, 2016; Roethig et al., 2009). Similarly, an aggregate of 12,218 smokers and 1,160 non-smokers were included in the NNAL analysis from 6 clinical studies (Benowitz et al., 2012; Benowitz, Goniewicz, et al., 2010; Hatsukami et al., 2010; Meier et al., 2020; St Helen et al., 2012; Yuan et al., 2016) and 14 observational studies (Al Ali et al., 2015; Ashley et al., 2010; Benowitz, Dains, et al., 2010; Benowitz, Goniewicz, et al., 2010; Branstetter & Muscat, 2013; Camacho et al., 2016; Czoli & Hammond, 2015; Derby et al., 2009; Radwan, Hecht, Carmella, & Loffredo, 2013; Rostron, 2013; Vogel, Carmella, Stepanov, Hatsukami, & Hecht, 2011; Wasserman et al., 2018; Wei, Blount, Xia, & Wang, 2016; Yuan et al., 2011). The data identified for the former smokers group (cessation group) consisted of mixed units, which was inconsistent with the criteria considered for statistical analysis and was therefore not included in this analysis.

Only total urinary NNAL (sum of NNAL and NNAL-glucuronide), reported as geometric means (excluding medians), were included in the analysis. Free NNAL data or total NNAL reported as the arithmetic mean was captured in the evidence table but was not included in the statistical analysis.

Summary of biomarker levels across groups

Carboxyhemoglobin. Not surprisingly, smokers had the highest percent COHb (5.21%) compared to former smokers (1.75%) and non-smokers (1.05%; Table 2a and Figure 1)

Table 2a. Percent Saturation Carboxyhemoglobin (% COHb)

Group	# Groups	Total Individuals	Average	Min	Max	S.D.	95% CI (LL)	95% CI (UL)
Non-smokers	2	1,949	1.05	0.23	1.45	0.61	0.04	2.07
Former Smokers	10	278	1.75	0.45	3.04	1.00	0.14	3.61
Smokers	61	16,311	5.21	2.26	6.99	0.56	3.91	6.00

SD: Standard Deviation; CI: Confidence Interval; LL: Lower Limit; UL: Upper Limit




Figure 1. Pooled weighted average estimates of COHb levels in non-smokers, former smokers, and current smokers

Significant differences ($p < 0.0001$) were observed for smokers compared to former smokers as well as to non-smokers. The former smokers group and non-smokers were not statistically different from each other ($p = 0.283$; Table 3a).

Table 3a. Statistical Results for Carboxyhemoglobin		
Group Comparison	Difference	P-value
Smokers vs. Non-smokers	4.30	< 0.0001
Smokers vs. Former Smokers	3.55	< 0.0001
Former Smokers vs. Non-smokers	0.76	0.283

P-values < 0.05 were considered statistically significantly different.

Nicotine Equivalents. The smokers group had the highest NEQ levels (13.81 mg/24 h) compared to former smokers (0.62 mg/24 h) and non-smokers (0.058 mg/24 h; Table 2b and Figure 2).

Table 2b. Nicotine Equivalents (mg/24 h)								
Group	#Groups	Total Individuals	Average	Min	Max	S.D.	95% CI (LL)	95% CI (UL)
Non-smokers	4	129	0.058	0.03	0.10	0.031	0.016	0.112
Former Smokers	3	55	0.62	0.30	1.00	0.35	0.070	1.281
Smokers	26	5,353	13.81	9.00	24.91	2.82	9.081	21.190

SD: Standard Deviation; CI: Confidence Interval; LL: Lower Limit; UL: Upper Limit




Figure 2. Pooled weighted average estimates of NEQ levels in non-smokers, former smokers, and current smokers

Statistically significant differences ($p < 0.0001$) were observed between smokers and non-smokers, and ($p < 0.001$) between smokers and former smokers. The former smokers group and non-smokers were not statistically different from each other ($p = 0.99$; Table 3b).

Table 3b. Statistical Results for Nicotine Equivalents (NEQ)		
Group Comparison	Difference	P-value
Smokers vs. Non-smokers	13.75	< 0.0001
Smokers vs. Former Smokers	13.20	< 0.001
Former Smokers vs. Non-smokers	0.55	0.99

P-values < 0.05 were considered statistically significantly different.

NNAL. Smokers had the highest level of NNAL (1.112 pmol/mg creatinine) compared to nonsmokers (0.008 pmol/mg creatinine; Table 2c and Figure 3).

Table 2c. NNAL (pmol/mg creatinine)								
Group	# Groups	Total Individuals	Average	Min	Max	S.D.	95 % CI (LL)	95 % CI (UL)
Non-smokers	3	1,160	0.008	0.002	0.014	0.0038	0.001	0.017
Smokers	36	12,218	1.112	0.182	1.842	0.5505	0.161	2.047

SD: Standard Deviation; CI: Confidence Interval; LL: Lower Limit; UL: Upper Limit



Figure 3. Pooled weighted average estimates of NNAL levels in non-smokers and current smokers

Statistical analysis indicated that NNAL levels in smokers and nonsmokers were significantly different ($p=0.0002$; Table 3c). The former smokers group was not included in the analysis.

Table 3c. Statistical Results for NNAL

Group Comparison	Difference	P-value
Smokers vs. Non-smokers	1.09	0.0002

P-values <0.05 were considered statistically significantly different.

Discussion

We report here the population estimate of pooled weighted averages of key BOEs of cigarette smoke to establish baseline levels for smokers and non-smokers. While there are many studies of BOEs in tobacco research, and many tobacco exposure biomarkers can be measured, it may not always be practical to measure every available biomarker in every evaluation (Chang et al., 2017). The availability of a single population level estimate should allow for estimating changes in the levels of these biomarkers among those adult smokers switching to a PRRP. Additionally, the population estimate among former smokers and non-smokers provides data to support relative comparisons for evaluating reductions in HPHCs among those who completely switched to PRRPs. Characterization of changes in exposure to HPHCs through BOEs provides important information regarding the reduced risk potential of a tobacco product (Chang et al., 2017).

Exposure to CO, a product of incomplete combustion of all organic materials, can be measured in the blood as COHb (as percent saturation of hemoglobin). COHb is a well-established biomarker for CO due to correlation with exhaled CO, dose response with cigarette smoking, and its relationship with smoking cessation (Hatsukami et al., 2006). The results reported in our analysis align with values reported in literature. For example, in the Total Exposure Study (Roethig et al., 2009), which was a cross-sectional study of U.S. cigarette smokers ($n = 3,585$) and non-smokers ($n = 1,077$), COHb distinguished smokers from non-smokers with a 3.6-fold difference. In our analysis we observed a 4.96-fold difference between smokers and non-smokers and 1.67-fold difference between smokers and former smokers. These observations provide useful information for designing studies on smoking cessation. COHb and CO are considered some of the most useful biomarkers for verifying smoking cessation in clinical trials. Additionally, COHb was not statistically different between former smokers (1.75%) and non-smokers (1.05%, Table 2a and Figure 1), demonstrating further, the utility of COHb as a marker of cessation.

Nicotine equivalents (NEQ) are the molar sum of urinary nicotine, cotinine, and several metabolites in the nicotine metabolic profile. NEQ is often considered the gold standard for daily nicotine intake. Unlike cotinine, NEQ accommodates factors that influence nicotine metabolism and exhibits a strong correlation with several tobacco BOEs, including hydroxy-PAHs and NNAL (Benowitz, Dains, Dempsey, Wilson, & Jacob, 2011). Similarly, 24 h urine NEQ has been suggested to be a surrogate measure for smoke exposure (Wang et al., 2011).

NNAL is the primary metabolite of NNK, a nicotine-derived nitrosamine ketone. NNAL is considered a good BOE because it is tobacco-specific and has a long half-life in biological fluids, around 10 to 45 days, making it less liable to variability in measurement due to transient changes in smoking behavior (Radwan et al., 2013; Roethig et al., 2009). In addition, NNAL correlates with other tobacco-specific markers, including cotinine and TNE (Goniewicz et al., 2009; Rostron et al., 2019). Several large epidemiologic studies, such as the National Health and Nutrition Examination Survey (NHANES), the Total Exposure Study, and the Multiethnic Cohort Study, report typical ranges of 1 to 2 pmol NNAL/mL of urine for smokers (Mendes et al., 2009; Roethig et al., 2008; Rostron, 2013;

Round et al., 2018). Rostron et al., (2019) reported NNAL concentration by tobacco use status of the NHANES 1999 to 2012 data. The average value for exclusive cigarette smokers of 217.6 pg/mg creatinine (converted to 1.04 pmol/mg creatinine) was comparable to the pooled weighted average (1.11 pmol/mg creatinine) reported in our analysis. We note that the mean values for non-tobacco users (non-smokers) was 0.98 pg/mg creatinine (converted to 0.005 pmol/mg creatinine), which was lower than the value reported in our analysis (0.008 pmol/mg creatinine). Rostron et al., (2019) reported NNAL concentration by cigarettes per day from the Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013 – 2014). This study reported mean levels ranging between 155.26 and 295.76 ng/g creatinine (converted to 0.742 and 1.413 pmol /mg creatinine). In our analysis we report a mean value of 1.11 pmol/mg creatinine, which is within the range reported by Rostron et al., (2019).

The analyses presented here should be considered in light of several limitations. The analysis included data from different study populations across different geographical regions representing a range of different smoking behaviors and different cigarette types. The estimates are dependent on the representativeness of the samples in the studies included. This will vary from population to population and over time, so using these estimates as benchmarks may have some limitations. However, estimating pooled weighted averages from a wide subset of study populations can provide a reasonable approximation of the overall population estimate. Additionally, the analytes were likely measured using different bioanalytic methodologies with possible differences in laboratory equipment, sensitivities, and calibration ranges. Nonetheless our analysis should be considered a general overall average as we pooled the aggregated data from different studies, taking into account the smoking status after weighting them by the sample size. In the case of NNAL, the analysis was limited to the largest body of data that either reported, or could be converted to, common units of NNAL excretion (pmol/mg creatinine). This work included only total urinary NNAL (sum of NNAL and NNAL-glucuronide) reported as geometric means. NNAL studies were excluded when data format (e.g., arithmetic means or median values) could not be converted to the unit of choice (pmol/mg creatinine) for the statistical analysis. Supplemental table 3 describes the 23 articles not included in the analysis (IDs 59, 25, 49, 15, 97, 51, 69, 41, 81, 44, 74, 9, 54, 79, 17, 75, 53, 13, 37, 16, 26, 67, 43) where the type of value (mean or arithmetic mean, median) are reported. Also, due to data gaps in the reporting of demographic information, this analysis ignores characteristics of subgroups such as race, gender, population size of the country, etc. Therefore, observations reported may not be generalizable of the world population. Nonetheless, our pooled weighted averages should be considered reasonable population estimates that may be useful as baseline values for COHb, NEQ, and NNAL. The availability of a single reliable weighted average estimate of BOEs can be useful in determining the relative changes in exposure in adult smokers switching to PRRPs at the population level.

References

1. Aberg, A. M., Sojka, B. N., Winsö, O., Abrahamsson, P., Johansson, G., & Larsson, J. E. (2009) Carbon monoxide concentration in donated blood: relation to cigarette smoking and other sources. *Transfusion*, 49(2), 347-353. doi:10.1111/j.1537-2995.2008.01951.x
2. Al Ali, R., Rastam, S., Ibrahim, I., Bazzi, A., Fayad, S., Shihadeh, A. L., . . . Maziak, W. (2015) A comparative study of systemic carcinogen exposure in waterpipe smokers, cigarette smokers and non-smokers. *Tobacco Control*, 24(2), 125-127. doi:10.1136/tobaccocontrol-2013-051206
3. Appleton, S., Liu, J., Lipowicz, P. J., & Sarkar, M. (2015). Effect of cigarette design on biomarkers of exposure, puffing topography and respiratory parameters *Inhalation Toxicology*, 27(3), 174-180. doi:10.3109/08958378.2015.1021980
4. Appleton, S., Olegario, R. M., & Lipowicz, P. J. (2014). TSNA exposure from cigarette smoking: 18 years of urinary NNAL excretion data *Regulatory Toxicology and Pharmacology*, 68(2), 269-274. doi:10.1016/j.yrtph.2013.07.013
5. Ashley, D. L., O'Connor, R. J., Bernert, J. T., Watson, C. H., Polzin, G. M., Jain, R. B., . . . McCraw, J. M. (2010) Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers. *Cancer Epidemiology, Biomarkers & Prevention*, 19(6), 1389-1398. doi:10.1158/1055-9965.Epi-10-0084
6. Barr, D. B., Wilder, L. C., Caudill, S. P., Gonzalez, A. J., Needham, L. L., & Pirkle, J. L. (2005) Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. *Environmental Health Perspectives*, 113(2), 192-200. doi:10.1289/ehp.7337
7. Benowitz, N., Goniewicz, M. L., Eisner, M. D., Lazcano-Ponce, E., Zielinska-Danch, W., Koszowski, B., . . . Jacob, P., 3rd. (2010) Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers. *Cancer Epidemiology, Biomarkers & Prevention*, 19(11), 2795-2800. doi:10.1158/1055-9965.Epi-10-0497
8. Benowitz, N. L., Dains, K. M., Dempsey, D., Havel, C., Wilson, M., & Jacob, P., 3rd. (2010) Urine menthol as a biomarker of mentholated cigarette smoking *Cancer Epidemiology, Biomarkers & Prevention*, 19(12), 3013-3019. doi:10.1158/1055-9965.Epi-10-0706
9. Benowitz, N. L., Dains, K. M., Dempsey, D., Wilson, M., & Jacob, P. (2011) Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure *Nicotine Tob Res*, 13(9), 772-783. doi:10.1093/ntr/ntr072
10. Benowitz, N. L., Dains, K. M., Hall, S. M., Stewart, S., Wilson, M., Dempsey, D., & Jacob, P., 3rd. (2012) Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. *Cancer Epidemiology, Biomarkers & Prevention*, 21(5), 761-769. doi:10.1158/1055-9965.Epi-11-0644
11. Branstetter, S. A., & Muscat, J. E. (2013). Time to first cigarette and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) levels in adult smokers: National Health and Nutrition Examination Survey (NHANES), 2007-2010. *Cancer Epidemiology, Biomarkers & Prevention*, 22(4), 615-622. doi:10.1158/1055-9965.Epi-12-0842
12. Camacho, O. M., Sommarström, J., Prasad, K., & Cunningham, A. (2016). Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study. *Pract Lab Med*, 5, 47-56. doi:10.1016/j.plabm.2016.05.003
13. Carmella, S. G., Chen, M., Han, S., Briggs, A., Jensen, J., Hatsukami, D. K., & Hecht, S. S. (2009) Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers *Chemical Research in Toxicology*, 22(4), 734-741. doi:10.1021/bx800479s
14. Chang, C. M., Edwards, S. H., Arab, A., Del Valle-Pinero, A. Y., Yang, L., & Hatsukami, D. K. (2017) Biomarkers of Tobacco Exposure: Summary of an FDA-Sponsored Public Workshop *Cancer Epidemiology, Biomarkers & Prevention*, 26(3), 291-302. doi:10.1158/1055-9965.epi-16-0675
15. Chen, G., Luo, S., Kozlovich, S., & Lazarus, P. (2016). Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers *Cancer Epidemiology, Biomarkers & Prevention*, 25(7), 1175-1184. doi:10.1158/1055-9965.Epi-15-1245
16. Church, T. R., Anderson, K. E., Caporaso, N. E., Geisser, M. S., Le, C. T., Zhang, Y., . . . Hecht, S. S. (2009) A prospectively measured serum biomarker for a tobacco-specific carcinogen and lung cancer in smokers. *Cancer Epidemiology, Biomarkers & Prevention*, 18(1), 260-266. doi:10.1158/1055-9965.Epi-08-0718
17. Church, T. R., Anderson, K. E., Le, C., Zhang, Y., Kampa, D. M., Benoit, A. R., . . . Hecht, S. S. (2010) Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers. *Biomarkers*, 15(4), 345-352. doi:10.3109/13547501003753881
18. Clark, W. F., Sontrop, J. M., Macnab, J. J., Suri, R. S., Moist, L., Salvadori, M., & Garg, A. X. (2011) Urine volume and change in estimated GFR in a community-based cohort study *Clinical*

Journal of the American Society of Nephrology, 6(11), 2634-2641. doi:10.2215/cjn.01990211

19. Cobb, C. O., Shihadeh, A., Weaver, M. F., & Eissenberg, T. (2011). Waterpipe tobacco smoking and cigarette smoking: a direct comparison of toxicant exposure and subjective effects *Nicotine Tob Res*, 13(2), 78-87. doi:10.1093/ntr/ntq212
20. Czoli, C. D., & Hammond, D. (2015). TSNA Exposure: Levels of NNAL Among Canadian Tobacco Users *Nicotine Tob Res*, 17(7), 825-830. doi:10.1093/ntr/ntu251
21. D'Ruiz, C. D., Graff, D. W., & Robinson, E. (2016). Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes. *BMC Public Health*, 16, 543. doi:10.1186/s12889-016-3236-1
22. Derby, K. S., Cuthrell, K., Caberto, C., Carmella, S., Murphy, S. E., Hecht, S. S., & Le Marchand, L. (2009). Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer. *International Journal of Cancer*, 125(10), 2418-2424. doi:10.1002/ijc.24585
23. Epanechnikov, V. A. (1969). Non-parametric estimation of a multivariate probability density. *Theory Probab. Appl.*, 14, 153-158. doi:10.1137/1114019
24. Feng, S., Kapur, S., Sarkar, M., Muhammad, R., Mendes, P., Newland, K., & Roethig, H. J. (2007). Respiratory retention of nicotine and urinary excretion of nicotine and its five major metabolites in adult male smokers. *Toxicology Letters*, 173(2), 101-106. doi:10.1016/j.toxlet.2007.06.016
25. Goniewicz, M. L., Gawron, M., Smith, D. M., Peng, M., Jacob, P., 3rd, & Benowitz, N. L. (2017). Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study. *Nicotine Tob Res*, 19(2), 160-167. doi:10.1093/ntr/ntw160
26. Goniewicz, M. L., Havel, C. M., Peng, M. W., Jacob, P., 3rd, Dempsey, D., Yu, L., . . . Benowitz, N. L. (2009). Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. *Cancer Epidemiology, Biomarkers & Prevention*, 18(12), 3421-3425. doi:10.1158/1055-9965.Epi-09-0874
27. Hatsukami, D., Joseph, A., LeSage, M., Jensen, J., Murphy, S., Pentel, P., . . . Hecht, S. (2007). Developing the science base for reducing tobacco harm *Nicotine and Tobacco Research*, 9(SUPPL. 4), 537-553. doi:10.1080/14622200701679040
28. Hatsukami, D. K., Benowitz, N. L., Rennard, S. I., Oncken, C., & Hecht, S. S. (2006). Biomarkers to assess the utility of potential reduced exposure tobacco products *Nicotine Tob. Res.*, 8, 600-622.
29. Hatsukami, D. K., Kotlyar, M., Hertsgaard, L. A., Zhang, Y., Carmella, S. G., Jensen, J. A., . . . Hecht, S. S. (2010). Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. *Addiction*, 105(2), 343-355. doi:10.1111/j.1360-0443.2009.02780.x
30. Hatsukami, D. K., Le, C. T., Zhang, Y., Joseph, A. M., Mooney, M. E., Carmella, S. G., & Hecht, S. S. (2006). Toxicant exposure in cigarette reducers versus light smokers *Cancer Epidemiology, Biomarkers & Prevention*, 15(12), 2355-2358. doi:10.1158/1055-9965.Epi-06-0240
31. Haziza, C., de La Bourdonnaye, G., Merlet, S., Benzimra, M., Ancerewicz, J., Donelli, A., . . . Lüdike, F. (2016). Assessment of the reduction in levels of exposure to harmful and potentially harmful constituents in Japanese subjects using a novel tobacco heating system compared with conventional cigarettes and smoking abstinence: A randomized controlled study in confinement. *Regulatory Toxicology and Pharmacology*, 81, 489-499. doi:10.1016/j.yrtph.2016.09.014
32. Haziza, C., de La Bourdonnaye, G., Skiada, D., Ancerewicz, J., Baker, G., Picavet, P., & Lüdike, F. (2016). Evaluation of the Tobacco Heating System 2.2. Part 8: 5-Day randomized reduced exposure clinical study in Poland. *Regulatory Toxicology and Pharmacology*, 81 Suppl 2 S139-S150. doi:10.1016/j.yrtph.2016.11.003
33. Haziza, C., de La Bourdonnaye, G., Skiada, D., Ancerewicz, J., Baker, G., Picavet, P., & Lüdike, F. (2017). Biomarker of exposure level data set in smokers switching from conventional cigarettes to Tobacco Heating System 2.2, continuing smoking or abstaining from smoking for 5 days. *Data Brief*, 10, 283-293. doi:10.1016/j.dib.2016.11.047
34. Hecht, S. S. (2004). Carcinogen derived biomarkers: applications in studies of human exposure to secondhand tobacco smoke *Tobacco Control*, 13 Suppl 1(Suppl 1), i48-56. doi:10.1136/tc.2002.002816
35. Hecht, S. S., Carmella, S. G., Chen, M., Dor Koch, J. F., Miller, A. T., Murphy, S. E., . . . Hatsukami, D. K. (1999). Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. *Cancer Research*, 59(3), 590-596.
36. Hecht, S. S., Yuan, J.-M., & Hatsukami, D. (2010). Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention *Chemical Research in Toxicology*, 23(6), 1001-1008. doi:10.1021/tx100056m
37. Heck, J. D. (2009). Smokers of menthol and nonmenthol cigarettes exhibit similar levels of biomarkers of smoke exposure *Cancer Epidemiology, Biomarkers & Prevention*, 18(2), 622-629. doi:10.1158/1055-9965.Epi-08-0550
38. Hedblad, B., Engström, G., Janzon, E., Berglund, G., & Janzon, L. (2006). COHb% as a marker of cardiovascular risk in never smokers: results from a population-based cohort study *Scandinavian Journal of Public Health*, 34(6), 609-615. doi:10.1080/14034940600590523
39. Hunter, J. E., & Schmidt, F. L. (1990). *Methods of meta-analysis: Correcting error and bias in research findings*. First Ed. Newbury Park, CA: Sage.
40. Kandel, D. B., Hu, M. C., Schaffran, C., Udry, J. R., & Benowitz, N. L. (2007). Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults *American Journal of Epidemiology*, 165(8), 901-910. doi:10.1093/aje/kwm010
41. Khariwala, S. S., Carmella, S. G., Stepanov, I., Fernandes, P., Lassig, A. A., Yueh, B., . . . Hecht, S. S. (2013). Elevated levels of 1-hydroxypyrene and N'-nitrosonor nicotine in smokers with head and neck cancer: A matched control study. *Head and Neck*, 35(8), 1096-1100. doi:10.1002/hed.23085
42. Kung, C. M., Wang, H. L., & Tseng, Z. L. (2008). Cigarette smoking exacerbates health problems in young men. *Clinical and Investigative Medicine. Medecine Clinique et Experimentale*, 31(3), E138-149. doi:10.25011/cim.v31i3.3471
43. Le Marchand, L., Derby, K. S., Murphy, S. E., Hecht, S. S., Hatsukami, D., Carmella, S. G., . . . Wang, H. (2008). Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. *Cancer Research*, 68(22), 9137-9140. doi:10.1158/0008-5472.Can-08-2271
44. Liu, J., Liang, Q., Frost-Pineda, K., Muhammad-Kah, R., Rimmer, L., Roethig, H., . . . Sarkar, M. (2011). Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. *Cancer Epidemiology, Biomarkers & Prevention*, 20(8), 1760-1769. doi:10.1158/1055-9965.Epi-10-0987
45. Lowe, F. J., Gregg, E. O., & McEwan, M. (2009). Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers *Clinical Chemistry and Laboratory Medicine*, 47(3), 311-320. doi:10.1515/ccclm.2009.069
46. Lüdike, F., Baker, G., Magnette, J., Picavet, P., & Weitkunat, R. (2017). Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents With the Tobacco Heating System 2.1 *Nicotine Tob Res*, 19(2), 168-175. doi:10.1093/ntr/ntw164
47. Lüdike, F., Haziza, C., Weitkunat, R., & Magnette, J. (2016). Evaluation of Biomarkers of Exposure in Smokers Switching to a Carbon-Heated Tobacco Product: A Controlled, Randomized, Open-Label 5-Day Exposure Study. *Nicotine Tob Res*, 18(7), 1606-1613. doi:10.1093/ntr/ntw022
48. Lüdike, F., Picavet, P., Baker, G., Haziza, C., Poux, V., Lama, N., & Weitkunat, R. (2018). Effects of Switching to the Tobacco Heating System 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings (Part 1). *Nicotine Tob Res*, 20(2),

161-172. doi:10.1093/ntr/ntw287

49. Martin, E. M., Clapp, P. W., Rebuli, M. E., Pawlak, E. A., Glista-Baker, E., Benowitz, N. L., . . . Jaspers, I. (2016)E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. *American Journal of Physiology Lung Cellular and Molecular Physiology*, 311(1), L135-144. doi:10.1152/ajplung.00170.2016
50. Martin, F., Vuillaume, G., Baker, G., Sponsiello-Wang, Z., Ricci, P. F., Lüdicke, F., & Weitkunat, R. (2018)Quantifying the risk-reduction potential of new Modified Risk Tobacco Products. *Regulatory Toxicology and Pharmacology*, 92 358-369. doi:10.1016/j.yrtph.2017.12.011
51. McKinney, D. L., Frost-Pineda, K., Oldham, M. J., Fisher, M. T., Wang, J., Gogova, M., & Kobal, G. (2014)Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers. *Nicotine Tob Res*, 16(7), 948-960. doi:10.1093/ntr/ntu009
52. Meier, E., Lindgren, B. R., Anderson, A., Reisinger, S. A., Norton, K. J., Jensen, J., . . . Hatsukami, D. K. (2020)A Randomized Clinical Trial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure. *Nicotine Tob Res*, 22(4), 473-481. doi:10.1093/ntr/ntz055
53. Mendes, P., Liang, Q., Frost-Pineda, K., Munjal, S., Walk, R. A., & Roethig, H. J. (2009)The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US. *Regulatory Toxicology and Pharmacology*, 55(1), 17-27. doi:10.1016/j.yrtph.2009.05.016
54. Morin, A., Shepperd, C. J., Eldridge, A. C., Poirier, N., & Voisine, R. (2011)Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure. *Regulatory Toxicology and Pharmacology*, 61(3 Suppl), S3-12. doi:10.1016/j.yrtph.2010.09.020
55. Muhammad-Kah, R. S., Hayden, A. D., Liang, Q., Frost-Pineda, K., & Sarkar, M. (2011)The relationship between nicotine dependence scores and biomarkers of exposure in adult cigarette smokers. *Regulatory Toxicology and Pharmacology*, 60(1), 79-83. doi:10.1016/j.yrtph.2011.02.008
56. Muscat, J. E., Chen, G., Knipe, A., Stellman, S. D., Lazarus, P., & Richie, J. P., Jr. (2009)Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation. *Cancer Epidemiology, Biomarkers & Prevention*, 18(1), 35-41. doi:10.1158/1055-9965.Epi-08-0744
57. Oliveri, D., Liang, Q., & Sarkar, M. (2020)Real-World Evidence of Differences in Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers. *Nicotine Tob Res*, 22(7), 1114-1122. doi:10.1093/ntr/ntz185
58. Prasad, G. L., Jones, B. A., Chen, P., & Gregg, E. O. (2016)A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers. *Clinical Chemistry and Laboratory Medicine*, 54(4), 633-642. doi:10.1515/ccim-2015-0594
59. Pulvers, K., Emami, A. S., Nollen, N. L., Romero, D. R., Strong, D. R., Benowitz, N. L., & Ahluwalia, J. S. (2018)Tobacco Consumption and Toxicant Exposure of Cigarette Smokers Using Electronic Cigarettes. *Nicotine Tob Res*, 20(2), 206-214. doi:10.1093/ntr/ntw333
60. Radwan, G., Hecht, S. S., Carmella, S. G., & Loffredo, C. A. (2013)Tobacco-specific nitrosamine exposures in smokers and nonsmokers exposed to cigarette or waterpipe tobacco smoke. *Nicotine Tob Res*, 15(1), 130-138. doi:10.1093/ntr/nts099
61. Rodgman, A., & Perletti, T. A. (2009). *The Chemical Components of Tobacco and Tobacco Smoke*. Boca Raton, FL: CRC Press Taylor and Francis Group.
62. Roethig, H. J., Feng, S., Liang, Q., Liu, J., Rees, W. A., & Zedler, B. K. (2008)A 12-month, randomized, controlled study to evaluate exposure and cardiovascular risk factors in adult smokers switching from conventional cigarettes to a second-generation electrically heated cigarette smoking system. *Journal of Clinical Pharmacology*, 48(5), 580-591. doi:10.1177/0091270008315316
63. Roethig, H. J., Munjal, S., Feng, S., Liang, Q., Sarkar, M., Walk, R. A., & Mendes, P. E. (2009)Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. *Nicotine Tob Res*, 11(10), 1216-1225. doi:10.1093/ntr/ntp126
64. Rostron, B. (2013). NNAL exposure by race and menthol cigarette use among U.S. smokers. *Nicotine Tob Res*, 15(5), 950-956. doi:10.1093/ntr/nts223
65. Rostron, B. L., Corey, C. G., Chang, J. T., van Bommel, D. M., Miller, M. E., & Chang, C. M. (2019)Associations of Cigarettes Smoked Per Day with Biomarkers of Exposure Among US Adult Cigarette Smokers in the Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014). *Cancer Epidemiology, Biomarkers & Prevention*. doi:10.1158/1055-9965.epi-19-0013
66. Round, E. K., Chen, P., Taylor, A. K., & Schmidt, E. (2018).Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum. *Nicotine Tob Res*. doi:10.1093/ntr/nty140
67. Sarkar, M., Kapur, S., Frost-Pineda, K., Feng, S., Wang, J., Liang, Q., & Roethig, H. (2008). Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies. *Nicotine Tob Res*, 10(12), 1761-1772. doi:10.1080/14622200802443718
68. Sarkar, M., Liu, J., Koval, T., Wang, J., Feng, S., Serafin, R., . . . Roethig, H. J. (2010)Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro snus. *Nicotine Tob. Res.*, 12, 105-116.
69. Sarkar, M., Muhammad-Kah, R., Liang, Q., Kapur, S., Feng, S., & Roethig, H. (2013). Evaluation of spot urine as an alternative to 24h urine collection for determination of biomarkers of exposure to cigarette smoke in adult smokers. *Environmental Toxicology and Pharmacology*, 36(1), 108-114. doi:10.1016/j.etap.2013.03.001
70. Scherer, G., Newland, K., Papadopoulou, E., & Minet, E. (2014). A correlation study applied to biomarkers of internal and effective dose for acrylonitrile and 4-aminobiphenyl in smokers. *Biomarkers*, 19(4), 291-301. doi:10.3109/1354750x.2014.910271
71. Schimmel, J., George, N., Schwarz, J., Yousif, S., Suner, S., & Hack, J. B. (2018).Carboxyhemoglobin Levels Induced by Cigarette Smoking Outdoors in Smokers. *Journal of Medical Toxicology*, 14(1), 68-73. doi:10.1007/s13181-017-0645-1
72. Schmidt, F. L., & Hunter, J. E. (2004). *Methods of meta-analysis: Correcting error and bias in research findings*. Second Ed. Third Ed (2014) (Schmidt & Hunter) Thousand Oaks, CA: Sage.
73. Shah, B. K., Nepal, A. K., Agrawal, M., & Sinha, A. K. (2012). *The effects of cigarette smoking on hemoglobin levels compared between smokers and non-smokers*. *Sunsari Technical College Journal*, 1(1), 42-44.
74. Shepperd, C. J., Eldridge, A. C., Errington, G., & Dixon, M. (2011)A study to evaluate the effect on Mouth Level Exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette. *Regulatory Toxicology and Pharmacology*, 61(3 Suppl), S13-24. doi:10.1016/j.yrtph.2011.05.011
75. Shepperd, C. J., Eldridge, A. C., Mariner, D. C., McEwan, M., Errington, G., & Dixon, M. (2009)A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure. *Regulatory Toxicology and Pharmacology*, 55(1), 97-109. doi:10.1016/j.yrtph.2009.06.006
76. Sørensen, L. T., Jørgensen, S., Petersen, L. J., Hemmingsen, U., Bülow, J., Loft, S., & Gottrup, F. (2009)Acute effects of nicotine and smoking on blood flow, tissue oxygen, and aerobic metabolism of the skin and subcutis. *Journal of Surgical Research*, 152(2), 224-230. doi:10.1016/j.jss.2008.02.066
77. St Charles, F. K., Krautter, G. R., Dixon, M., & Mariner, D. C. (2006)A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites. *Psychopharmacology*, 189(3), 345-354. doi:10.1007/s00213-006-0586-x
78. St Helen, G., Goniewicz, M. L., Dempsey, D., Wilson, M., Jacob, P., 3rd, & Benowitz, N. L. (2012)Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers. *Chemical Research in Toxicology*, 25(4), 952-964. doi:10.1021/tx300043k
79. Strasser, A. A., Benowitz, N. L., Pinto, A. G., Tang, K. Z., Hecht, S. S., Carmella, S. G., . . . Lerman, C. E. (2011)Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker

- level. *Cancer Epidemiology, Biomarkers & Prevention*, 20(2), 234-238. doi:10.1158/1055-9965.Epi-10-0674
80. Stratton, K., Shetty, P., Wallace, R., & Bondurant, S. (2001). Clearing the smoke: the science base for tobacco harm reduction--executive summary. *Tobacco Control*, 10(2), 189-195.
 81. Ter-Minassian, M., Asomaning, K., Zhao, Y., Chen, F., Su, L., Carmella, S. G., . . . Christiani, D. C. (2012). Genetic variability in the metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL). *International Journal of Cancer*, 130(6), 1338-1346. doi:10.1002/ijc.26162
 82. Theophilus, E. H., Coggins, C. R., Chen, P., Schmidt, E., & Borgerding, M. F. (2015). Magnitudes of biomarker reductions in response to controlled reductions in cigarettes smoked per day: a one-week clinical confinement study. *Regulatory Toxicology and Pharmacology*, 71(2), 225-234. doi:10.1016/j.yrtph.2014.12.023
 83. Theron, A., Schultz, C., Ker, J. A., & Falzone, N. (2010). Carboxyhaemoglobin levels in water-pipe and cigarette smokers. *South African Medical Journal*, 100(2), 122-124. doi:10.7196/samj.3462
 84. Tran, C. T., Bosilkovska, M., de La Bourdonnaye, G., Blanc, N., & Haziza, C. (2020). Reduced levels of biomarkers of exposure in smokers switching to the Carbon-Heated Tobacco Product 1.0: a controlled, randomized, open-label 5-day exposure trial. *Scientific Reports*, 10(1), 19227. doi:10.1038/s41598-020-76222-y
 85. Tricker, A. R., Jang, I. J., Martin Leroy, C., Lindner, D., & Dempsey, R. (2012). Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 4: Eight-day randomized clinical trial in Korea. *Regulatory Toxicology and Pharmacology*, 64(2 Suppl), S45-53. doi:10.1016/j.yrtph.2012.08.013
 86. Tricker, A. R., Kanada, S., Takada, K., Leroy, C. M., Lindner, D., Schorp, M. K., & Dempsey, R. (2012). Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 5: 8-Day randomized clinical trial in Japan. *Regulatory Toxicology and Pharmacology*, 64(2 Suppl), S54-63. doi:10.1016/j.yrtph.2012.08.003
 87. Tricker, A. R., Stewart, A. J., Leroy, C. M., Lindner, D., Schorp, M. K., & Dempsey, R. (2012). Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 3: Eight-day randomized clinical trial in the UK. *Regulatory Toxicology and Pharmacology*, 64(2 Suppl), S35-44. doi:10.1016/j.yrtph.2012.08.010
 88. U. S. Food and Drug Administration. (2012). Harmful and potentially harmful constituents in tobacco products and tobacco smoke: established list. Retrieved from <https://www.fda.gov/tobacco-products/rules-regulations-and-guidance/harmful-and-potentially-harmful-constituents-tobacco-products-and-tobacco-smoke-established-list>
 89. Unverdorben, M., Mostert, A., Munjal, S., van der Bijl, A., Potgieter, L., Venter, C., . . . Roethig, H. J. (2010). Acute effects of cigarette smoking on pulmonary function. *Regulatory Toxicology and Pharmacology*, 57(2-3), 241-246. doi:10.1016/j.yrtph.2009.12.013
 90. van Staden, S. R., Groenewald, M., Engelbrecht, R., Becker, P. J., & Hazelhurst, L. T. (2013). Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes. *South African Medical Journal*, 103(11), 865-868. doi:10.7196/samj.6887
 91. Vogel, R. I., Carmella, S. G., Stepanov, I., Hatsukami, D. K., & Hecht, S. S. (2011). The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers. *Biomarkers*, 16(6), 491-497. doi:10.3109/1354750x.2011.598565
 92. Wang, J., Liang, Q., Mendes, P., & Sarkar, M. (2011). Is 24h nicotine equivalents a surrogate for smoke exposure based on its relationship with other biomarkers of exposure? *Biomarkers*, 16(2), 144-154. doi:10.3109/1354750x.2010.536257
 93. Wang, J., Roethig, H. J., Appleton, S., Werley, M., Muhammad-Kah, R., & Mendes, P. (2010). The effect of menthol containing cigarettes on adult smokers' exposure to nicotine and carbon monoxide. *Regulatory Toxicology and Pharmacology*, 57(1), 24-30. doi:10.1016/j.yrtph.2009.12.003
 94. Wasserman, E. J., Reilly, S. M., Goel, R., Foulds, J., Richie, J. P., Jr., & Muscat, J. E. (2018). Comparison of Biomarkers of Tobacco Exposure between Premium and Discount Brand Cigarette Smokers in the NHANES 2011-2012 Special Sample. *Cancer Epidemiology, Biomarkers & Prevention*, 27(5), 601-609. doi:10.1158/1055-9965.Epi-17-0869
 95. Wei, B., Blount, B. C., Xia, B., & Wang, L. (2016). Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012 *Journal of Exposure Science & Environmental Epidemiology*, 26(3), 249-256. doi:10.1038/jes.2014.88
 96. Xavier, R. F., Ramos, D., Ito, J. T., Rodrigues, F. M., Bertolini, G. N., Macchione, M., . . . Ramos, E. M. (2013). Effects of cigarette smoking intensity on the mucociliary clearance of active smokers. *Respiration*, 86(6), 479-485. doi:10.1159/000348398
 97. Yang, J. Y., Ahn, H. K., Lee, S. W., Han, Y. J., Oh, Y. J., Velázquez-Armenta, E. Y., & Nava-Ocampo, A. A. (2015). Simple high-throughput analytical method using ultra-performance liquid chromatography coupled with tandem mass spectrometry to quantify total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine. *Clinical Chemistry and Laboratory Medicine*, 53(8), 1249-1257. doi:10.1515/cclm-2014-0829
 98. Yuan, J. M., Gao, Y. T., Murphy, S. E., Carmella, S. G., Wang, R., Zhong, Y., . . . Hecht, S. S. (2011). Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers. *Cancer Research*, 71(21), 6749-6757. doi:10.1158/0008-5472.Can-11-0209
 99. Yuan, J. M., Stepanov, I., Murphy, S. E., Wang, R., Allen, S., Jensen, J., . . . Hecht, S. S. (2016). Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers. *Cancer Prevention Research (Philadelphia, Pa.)*, 9(5), 396-405. doi:10.1158/1940-6207.Capr-15-0380
 100. Yuki, D., Takeshige, Y., Nakaya, K., & Futamura, Y. (2018). Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese smokers using a novel tobacco vapor product compared with conventional cigarettes and smoking abstinence. *Regulatory Toxicology and Pharmacology*, 96, 127-134. doi:10.1016/j.yrtph.2018.05.001

Additional References Reviewed

1. Benowitz NL, St Helen G, Nardone N, Cox LS, Jacob P. (2020). Urine Metabolites for Estimating Daily Intake of Nicotine from cigarette smoking. *Nicotine Tob Res*. 6;22(2):288-292.
2. Cano M, Reynaga DD, Belluzzi JD, Loughlin SE, Leslie F. (2020). Chronic exposure to cigarette smoke extract upregulates nicotinic receptor binding in adult and adolescent rats. *Neuropharmacology*. 181:108308.
3. Carroll DM, Allenzara A, Jensen J, Stepanov I, Hecht S, Murphy S, Luo X, Donny E, Hatsukami DK. (2019). Biomarkers of Exposure and Potential Harm among Natural American Spirit Smokers. *Tob Regul Sci*. 5(4):339-351.
4. Cheng YC, Reyes-Guzman CM, Christensen CH, Rostron BL, Edwards KC, Wang L, Feng J, Jarrett JM, Ward CD, Xia B, Kimmel HL, Conway K, Leggett C, Taylor K, Lawrence C, Niaura R, Travers MJ, Hyland A, Hecht SS, Hatsukami DK, Goniewicz ML, Borek N, Blount BC, van Bommel DM. (2020). Biomarkers of Exposure among Adult Smokeless Tobacco Users in the Population Assessment of Tobacco and Health Study (Wave 1, 2013-2014). *Cancer Epidemiol Biomarkers Prev*. 29(3):659-667.
5. Donny, E.C., Denlinger, R.L., Tidey, J.W., Koopmeiners, J.S., Benowitz, N.L., Vandrey, R.G., al'Absi, M., Carmella, S.G., Cinciripini, P.M., Dermody, S.S., Drobes, D.J., Hecht, S.S., Jensen, J., Lane, T., Le, C.T., McClernon, F.J., Montoya, I.D., Murphy, S.E., Robinson, J.D., Stitzer, M.L., Strasser, A.A., Tindle, H., and Hatsukami, D.K. (2015). Randomized trial of reduced nicotine standards for cigarettes. *N Engl J Med* 373(14): 1340-1349.
6. Dorey A., Scheerlinck P., Nguyen H., Albertson T. (2020). Acute and chronic Carbon Monoxide toxicity from tobacco smoking. *Mil Med*. 185(1-2):e61-e67.
7. Hatsukami D.K., Luo, X., Jensen, J.A., al'Absi, M., Allen S.S., Carmella S.G., Chen, M., Cinciripini, P.M., Denlinger, R., Drobes, D.J., Koopmeiners, J.S., Lane, T., Chap T.L., Leischow, S., Luo K., McClernon, F.S., Murphy, S.E., Paiano, V., Robinson, J.D., Severson, H. Sipe, C., Strasser, A.A., Tang, M.K., Vandrey, R., Hecht, S.S., Benowitz, N.L., Donny, E.C. (2018). Effect of immediate vs gradual reduction in nicotine content of cigarettes on biomarkers of smoke exposure: A randomized clinical trial. *JAMA* 320(9): 880-891.

8. Hutcherson JA, Gogenini H, Lamont GJ, Miller DP, Nowakowska Z, Lasica AM, Liu C, Potempa J, Lamont RJ, Yoder-Himes D, Scott DA (2020). Porphyromonas gingivalis genes conferring fitness in a tobacco-rich environment. *Mol Oral Microbiol.* 35(1):10-18.
9. Jacob P, St Helen G, Yu L, Nardone N, Havel C, Cheung P, Benowitz NL (2020). Biomarkers of Exposure for Dual Use of Electronic Cigarettes and Combustible Cigarettes: Nicotelline, NNAL, and Total Nicotine Equivalents. *Nicotine Tob Res.* 22(7):1107-1113.
10. Jay J, Pfau Miller EL, Huang NJ, Cohen G, Graff DW (2020). Five-Day Changes in Biomarkers of Exposure Among Adult Smokers After Completely Switching from Combustible Cigarettes to a Nicotine-Salt Pod System. *Nicotine Tob Res.* 22(8):1285-1293.
11. Kunal S., Qiwei, L., Raheema, M-K., Mohamadi, S. (2017). Evaluating the relationship between biomarkers of potential harm and biomarkers of tobacco exposure among current, past, and nonsmokers: data from the National Health and Nutrition Examination Survey 2007-2012. *Biomarkers* 22(5):403-412. doi: 10.1080/1354750X.2016.1201536.
12. Lüdicke F, Ansari SM, Lama N, Blanc N, Bosilkovska M, Donelli A, Picavet P, Baker G, Haziza C, Peitsch M, Weitkunat R (2019). Effects of Switching to a Heat-Not-Burn Tobacco Product on Biologically Relevant Biomarkers to Assess a Candidate Modified Risk Tobacco Product: A Randomized Trial. *Cancer Epidemiol Biomarkers Prev.* 28(11):1934-1943.
13. Meier E, Vandrey R, Rubin N, Pacek LR, Jensen JA, Donny EC, Hecht SS, Carmella SG, Murphy SE, Luo X, Stepanov I, Ikuemonisan J, Severson H, Al'absi M, Hatsukami DK (2020). Cigarette Smokers Versus Cousers of Cannabis and Cigarettes: Exposure to Toxicants. *Nicotine Tob Res.* 22(8):1383-1389.
14. Meier E, Lindgren BR, Anderson A, Reisinger SA, Norton KJ, Jensen J, Strayer L, Dick L, Tang MK, Chen M, Carmella SG, Hecht SS, Murphy SE, Yang J, Stepanov I, O'Connor RJ, Shields PG, Hatsukami DK (2020). A Randomized Clinical Trial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure. *Nicotine Tob Res.* 22(4):473-481.
15. Nemukula M, Mogale MA, Mkhondo HB, Bekker L. (2020). Association of Carboxyhemoglobin Levels with Peripheral Arterial Disease in Chronic Smokers Managed at Dr George Mukhari Academic Hospital. *Int J Environ Res Public Health* 2;17(15):5581.
16. Rostron B.L., Chang, C.M., van Bommel D.M., Xia Y., Blount B.C. (2015). Nicotine and Toxicant Exposure among U.S. Smokeless Tobacco Users: Results from 1999 to 2012 National Health and Nutrition Examination Survey Data. *Cancer Epidemiol Biomarkers Prev.* 24(12): 1829-1837.
17. Sakaguchi C., Miura N., Ohara H., Nagata Y. (2019). Effects of reduced exposure to cigarette smoking on changes in biomarkers of potential harm in adult smokers: Results of combined analysis of two clinical studies. *Biomarkers* 24(5):457-468.
18. Sipe CJ, Koopmeiners JS, Donny EC, Hatsukami DK, Murphy SE. (2020). UGT2B10 Genotype Influences Serum Cotinine Levels and Is a Primary Determinant of Higher Cotinine in African American Smokers. *Cancer Epidemiol Biomarkers Prev.* 29(8):1673-1678.
19. St. Helen G, Benowitz NL, Ahluwalia JS, Tyndale RF, Addo N, Gregorich SE, Pérez-Stable EJ, Cox LS (2019). Black Light Smokers: How Nicotine Intake and Carcinogen Exposure Differ Across Various Biobehavioral Factors. *J Natl Med Assoc.* 111(5):509-520.
20. Stram DO, Park SL, Haiman CA, Murphy SE, Patel Y, Hecht SS, Le Marchand L. (2019). Racial/Ethnic Differences in Lung Cancer Incidence in the Multiethnic Cohort Study: An Update. *J Natl Cancer Inst.* 111(8):811-819.
21. Tran CT, Felber Medlin L, Lama N, Taranu B, Ng W, Haziza C, Picavet P, Baker (2019). Biological and functional changes in healthy adult smokers who are continuously abstinent from smoking for one year: Protocol for a prospective, observational, multicenter cohort study. *JMIR Res Protoc.* 7;8(6):e12138.
22. Wang Y, Narayanapillai SC, Hu Q, Fujioka N, Xing C (2019). Detection and quantification of 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) from smoker albumin and its potential as a surrogate biomarker of tobacco-specific nitrosamines exposure and bioactivation. *Toxicol Lett.* 311:11-16.
23. Wang Y, Narayanapillai SC, Tessier KM, Strayer LG, Upadhyaya P, Hu Q, Kingston R, Salloum RG, Lu J, Hecht SS, Hatsukami DK, Fujioka N, Xing C (2020). The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active Smokers. *Cancer Prev Res (Phila).* 13(5):483-492.

Supplemental Appendix A

NNAL Conversion Table

Evidence Tables:

1. COHB: Complete list of studies included in the analysis; summary with study types
2. NEQ: Complete list of studies included in the analysis; summary with study types
3. NNAL: Complete list of studies included in the analysis; summary with study types

NNAL Conversion Table

						References:						
	NNAL Conversion						Urine 1.8 L/day (Median) (Clark et al., CJASN 6(11):2634-2641 (2011) Ref. 18.					
							0.8 -2 L/day (Medline Plus Medical Encyclopedia) https://medlineplus.gov/ency/article/003425.htm . Accessed 18-Nov. 2020.					
	1 pg	1E-12	g				Creatinine: 122.665 ± 24.025 mg/dL (1226.65 ± 240.25 mg/L)					
	1 L	1000	mL				From Barr et al 2005 (ALL adults > 20years old) Ref. 6.					
	NNAL MW	209.24	g/mol				Normal urine creatinine values generally range from 955 to 2,936					
	1 mol/L	1E-12	pmol/L				mg per 24 h for males, and 601 to 1,689 mg per 24 hs for					
	Total 24h Urine	1,800	mL				females, according to the Mayo Clinic. https://www.healthline.com/health/high-creatinine-symptoms#desired-range . Accessed 20-Nov. 2020.					
	Creatinine	2208	mg/24h				Min	601	mg/24 h			
	BW						Likely	1226.65x1.8L = 2208	mg/24 h			
							Max	2936	mg/24 h			
Study ID	pg/mL	pg/24h urine	ng/24h urine	pmol/L	Total pmol		Creatinine mg/24 h	pg NNAL/mg creatinine	ng NNAL/ mg creatinine	pmol NNAL/ mg creatinine	Reference	Published value
1										1.14	Meier et al 2020, Ref. 52	1.14



1											1.29	Meier et al 2020, Ref. 52	1.29
1											1.38	Meier et al 2020, Ref. 52	1.38
1											1.31	Meier et al 2020, Ref. 52	1.31
1											1.15	Meier et al 2020, Ref. 52	1.15
1											1.43	Meier et al 2020, Ref. 52	1.43
2											0.008	Wasserman et al 2018, Ref. 94	0.008
2											0.77	Wasserman et al 2018, Ref. 94	0.77
2											1.474	Wasserman et al 2018, Ref. 94	1.474
2											1.217	Wasserman et al 2018, Ref. 94	1.217
3											N/A		N/A
4											N/A		N/A
5											N/A		N/A
6											N/A		N/A
7			307720	307.72		1470.655706	2208		139.365942	0.139365942	0.666	Camacho et al 2016, Ref. 12	307.72
7			188000	188		898.4897725	2208		85.14492754	0.085144928	0.407	Camacho et al 2016, Ref. 12	188
7			249000	249		1190.021028	2208		112.7717391	0.112771739	0.539	Camacho et al 2016, Ref. 12	249
7			333000	333		1591.473906	2208		150.8152174	0.150815217	0.721	Camacho et al 2016, Ref. 12	333
7			149000	149		712.1009367	2208		67.48188406	0.067481884	0.323	Camacho et al 2016, Ref. 12	149
7			195000	195		931.9441789	2208		88.31521739	0.088315217	0.422	Camacho et al 2016, Ref. 12	195
7			266000	266		1271.267444	2208		120.4710145	0.120471014	0.576	Camacho et al 2016, Ref. 12	266
8											0.89	Yuan et al 2016, Ref. 99	0.89
8											0.85	Yuan et al 2016, Ref. 99	0.85
8											0.94	Yuan et al 2016, Ref. 99	0.94
9	200	360000	360	955.8401835	1720.51233		2208		163.0434783	0.163043478	0.779	Wei et al 2016, Ref. 95	200
9	1.08	1944	1.944	5.161536991	9.290766584		2208		0.880434783	0.000880435	0.004	Wei et al 2016, Ref. 95	1.08
9	195	351000	351	931.9441789	1677.499522		2208		158.9673913	0.158967391	0.760	Wei et al 2016, Ref. 95	195
9	205	369000	369	979.7361881	1763.525139		2208		167.1195652	0.167119565	0.799	Wei et al 2016, Ref. 95	205
9		476928	476.928		2279.334735		2208		216	0.216	1.032	Wei et al 2016, Ref. 95	216
9		2627.52	2.62752		12.557446		2208		1.19	0.00119	0.006	Wei et al 2016, Ref. 95	1.19
9		415104	415.104		1983.865418		2208		188	0.188	0.898	Wei et al 2016, Ref. 95	188
9		565248	565.248		2701.43376		2208		256	0.256	1.223	Wei et al 2016, Ref. 95	256
10	71.2	128160	128.16	340.2791053	612.5023896		2208		58.04347826	0.058043478	0.277	Czoli & Hammond, 2015, Ref. 20	71.2
10	82	181056	181.056		865.3030013		2208		82	0.082	0.392	Czoli & Hammond, 2015, Ref. 20	82
11											N/A		
12											N/A		
13	10.7	19260	19.26	51.13744982	92.04740967		2208		8.722826087	0.008722826	0.042	Ali et al 2015, Ref. 2	10.7
13	46.8	84240	84.24	223.6666029	402.5998853		2208		38.15217391	0.038152174	0.182	Ali et al 2015, Ref. 2	46.8
13		19651.2	19.6512		93.91703307		2208		8.9	0.0089	0.043	Ali et al 2015, Ref. 2	8.9
13		86332.8	86.3328		412.601797		2208		39.1	0.0391	0.187	Ali et al 2015, Ref. 2	39.1
14											N/A		
15	460	828000	828	2198.432422	3957.17836		2208		375	0.375	1.792	Branstetter, Muscat 2013, Ref. 11	0.46
15	470	846000	846	2246.224431	4043.203976		2208		383.1521739	0.383152174	1.831	Branstetter, Muscat 2013, Ref. 11	0.47
15	450	810000	810	2150.640413	3871.152743		2208		366.8478261	0.366847826	1.753	Branstetter, Muscat 2013, Ref. 11	0.45
16											1.22	Radwan et al 2013, Ref. 60	1.22
17		584016	584.016		2791.129803		2208		264.5	0.2645	1.264	Rostron B. 2013, Ref. 64	264.5
17		850963.2	850.9632		4066.924106		2208		385.4	0.3854	1.842	Rostron B. 2013, Ref. 64	385.4
18											N/A		
19											N/A		
20		461472	461.472		2205.467406		2208		209	0.209	1.00	Benowitz et al 2012, Ref. 10	0.209
20		415104	415.104		1983.865418		2208		188	0.188	0.90	Benowitz et al 2012, Ref. 10	0.188
20		461472	461.472		2205.467406		2208		209	0.209	1.00	Benowitz et al 2012, Ref. 10	0.209
20		646944	646.944		3091.875358		2208		293	0.293	1.40	Benowitz et al 2012, Ref. 10	0.293
20		554208	554.208		2648.671382		2208		251	0.251	1.20	Benowitz et al 2012, Ref.	0.251



											10		
20		368736	368.736		1762.26343		2208		167	0.167	0.80	Benowitz et al 2012, Ref. 10	0.167
20		600576	600.576		2870.27337		2208		272	0.272	1.30	Benowitz et al 2012, Ref. 10	0.272
20		554208	554.208		2648.671382		2208		251	0.251	1.20	Benowitz et al 2012, Ref. 10	0.251
20		322368	322.368		1540.661441		2208		146	0.146	0.70	Benowitz et al 2012, Ref. 10	0.146
21											0.014	St Helen et al 2012, Ref. 78	0.014
21											0.0018	St Helen et al 2012, Ref. 78	0.0018
21											0.88	St Helen et al 2012, Ref. 78	0.88
21											1.05	St Helen et al 2012, Ref. 78	1.05
22											0.28	Yuan et al 2011, Ref. 98	0.28
22											0.2	Yuan et al 2011, Ref. 98	0.2
23				1120	2016		2208				0.913	Vogel et al 2011, Ref. 91	1.12
23				610	1098		2208				0.497	Vogel et al 2011, Ref. 91	0.61
23				920	1656		2208				0.750	Vogel et al 2011, Ref. 91	0.92
23				1250	2250		2208				1.019	Vogel et al 2011, Ref. 91	1.25
23				810	1458		2208				0.660	Vogel et al 2011, Ref. 91	0.81
23				1360	2448		2208				1.109	Vogel et al 2011, Ref. 91	1.36
23				820	1476		2208				0.668	Vogel et al 2011, Ref. 91	0.82
23				2950	5310		2208				2.405	Vogel et al 2011, Ref. 91	2.95
23				2330	4194		2208				1.899	Vogel et al 2011, Ref. 91	2.33
23				1180	2124		2208				0.962	Vogel et al 2011, Ref. 91	1.18
23				2060	3708		2208				1.679	Vogel et al 2011, Ref. 91	2.06
23				2140	3852		2208				1.745	Vogel et al 2011, Ref. 91	2.14
24											N/A		
25											N/A		
26											N/A		
27											N/A		
28											N/A		
29												Benowitz et al 2010, Ref. 7	
											0.9		0.9
29											1.2	Benowitz et al 2010, Ref. 7	1.2
30		492384	492.384		2353.202065		2208		223	0.223	1.07	Benowitz et al 2010, Ref. 8	223
30		264960	264.96		1266.297075		2208		120	0.12	0.57	Benowitz et al 2010, Ref. 8	120
31		158976	158.976		759.7782451		2208		72	0.072	0.344	Ashley et al 2010, Ref. 5	0.072
31		640320	640.32		3060.217932		2208		290	0.29	1.386	Ashley et al 2010, Ref. 5	0.29
31		479136	479.136		2289.887211		2208		217	0.217	1.037	Ashley et al 2010, Ref. 5	0.217
31		240672	240.672		1150.219843		2208		109	0.109	0.521	Ashley et al 2010, Ref. 5	0.109
31		306912	306.912		1466.794112		2208		139	0.139	0.664	Ashley et al 2010, Ref. 5	0.139
32											N/A		
33											0.96	Hatsukami et al 2010, Ref. 29	0.96
33											0.92	Hatsukami et al 2010, Ref. 29	0.92
33											1.06	Hatsukami et al 2010, Ref. 29	1.06
34				640	1152		2208				0.522	Derby et al 2009, Ref. 22	0.64
34				980	1764		2208				0.799	Derby et al 2009, Ref. 22	0.98
34				850	1530		2208				0.693	Derby et al 2009, Ref. 22	0.85
34				1130	2034		2208				0.921	Derby et al 2009, Ref. 22	1.13
34				700	1260		2208				0.571	Derby et al 2009, Ref. 22	0.7
34				600	1080		2208				0.489	Derby et al 2009, Ref. 22	0.6
34				820	1476		2208				0.668	Derby et al 2009, Ref. 22	0.82
35											N/A		
36											N/A		
37											N/A		
38											N/A		
39											N/A		
40											N/A		
41		960480	960.48		4590.326897		2208		435	0.435	2.08	Goniewicz et al 2009, Ref. 26	435
41		82137.6	82.1376		392.5520933		2208		37.2	0.0372	0.18	Goniewicz et al 2009, Ref. 26	37.2
42											N/A		

Evidence Tables:

Supplemental Table 1 COHb: Complete list of studies included in the analysis; summary with study types

Ref. ID	PUB_Years0	PUB_Years	PUB_Type	PUB_Name	PUB_Country	PUB_Authors	PUB_Company	PUB_Code_comp	PUB_Title	PUB_relevant	PUB_Available	PUB_use	STUD_Type	STUD_Method	STUD_As
71	2018	2017	Research article	Journal of Medical Toxicology	USA	Schimmel J., George N., Schwarz, N., Yousif S., Suner S., Hack J.B.	Academia	Other	Carboxyhemoglobin Levels Induced by Cigarette Smoking Outdoors in Smokers	NO	NO	NO	Prospective cohort	NA	NA
71	2018	2017	Research article	Journal of Medical Toxicology	USA	Schimmel J., George N., Schwarz, N., Yousif S., Suner S., Hack J.B.	Academia	Other	Carboxyhemoglobin Levels Induced by Cigarette Smoking Outdoors in Smokers	NO	NO	NO	Prospective cohort	NA	NA
71	2018	2017	Research article	Journal of Medical Toxicology	USA	Schimmel J., George N., Schwarz, N., Yousif S., Suner S., Hack J.B.	Academia	Other	Carboxyhemoglobin Levels Induced by Cigarette Smoking Outdoors in Smokers	NO	NO	NO	Prospective cohort	NA	NA
49	2018	2018	Research article	Regulatory Toxicology and Pharmacology	Switzerland Poland	Florian Martin, Gregory Vuillaume, GizelleBaker, Zheng Sponsiello-Wang, Paolo F. Ricci, Frank Lüdicke, Rolf Weitkunat	Academia PMI	Mixed	Quantifying the risk-reduction potential of new Modified Risk Tobacco Products	NO	YES	NO	Assessment of Risk	Randomized, controlled, open label, 3-arm parallel design	NA
49	2018	2018	Research article	Regulatory Toxicology and Pharmacology	Switzerland Poland	Florian Martin, Gregory Vuillaume, GizelleBaker, Zheng Sponsiello-Wang, Paolo F. Ricci, Frank Lüdicke, Rolf Weitkunat	Academia PMI	Mixed	Quantifying the risk-reduction potential of new Modified Risk Tobacco Products	NO	YES	NO	Assessment of Risk	Randomized, controlled, open label, 3-arm parallel design	NA
49	2018	2018	Research article	Regulatory Toxicology and Pharmacology	Switzerland Poland	Florian Martin, Gregory Vuillaume, GizelleBaker, Zheng Sponsiello-Wang, Paolo F. Ricci, Frank Lüdicke, Rolf Weitkunat	Academia PMI	Mixed	Quantifying the risk-reduction potential of new Modified Risk Tobacco Products	NO	YES	NO	Assessment of Risk	Randomized, controlled, open label, 3-arm parallel design	NA
33	2017	2017	Research article	Data in Brief	USA	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Biomarker of exposure level data set in smokers switching from conventional cigarettes to THS 2.2, continuing smoking or abstaining from smoking for 5days	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA
33	2017	2017	Research article	Data in Brief	USA	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Biomarker of exposure level data set in smokers switching from conventional cigarettes to THS 2.2, continuing smoking or abstaining from smoking for 5days	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA
33	2017	2017	Research article	Data in Brief	USA	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Biomarker of exposure level data set in smokers switching from conventional cigarettes to THS 2.2, continuing smoking or abstaining from smoking for 5days	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA
33	2017	2017	Research article	Data in Brief	USA	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Biomarker of exposure level data set in smokers switching from conventional cigarettes to THS 2.2, continuing smoking or abstaining from smoking for 5days	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA
33	2017	2017	Research article	Data in Brief	USA	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Biomarker of exposure level data set in smokers switching from conventional cigarettes to THS 2.2, continuing smoking or abstaining from smoking for 5days	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA

						Gizelle Baker, Patrick Picavet, Frank Lüdicke			abstaining from smoking for 5days						center study in confinement	
46	2017	2017	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Gizelle Baker, John Magnette, Patrick Picavet, Rolf Weitkunat	PMI	Tobacco	Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents with the THS 2.1	YES	YES	YES	Clinical trial	Randomized, open-label, two-parallel groups	NA	
46	2017	2017	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Gizelle Baker, John Magnette, Patrick Picavet, Rolf Weitkunat	PMI	Tobacco	Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents with the THS 2.1	YES	YES	YES	Clinical trial	Randomized, open-label, two-parallel groups	NA	
46	2017	2017	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Gizelle Baker, John Magnette, Patrick Picavet, Rolf Weitkunat	PMI	Tobacco	Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents with the THS 2.1	YES	YES	YES	Clinical trial	Randomized, open-label, two-parallel groups	NA	
46	2017	2017	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Gizelle Baker, John Magnette, Patrick Picavet, Rolf Weitkunat	PMI	Tobacco	Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents with the THS 2.1	YES	YES	YES	Clinical trial	Randomized, open-label, two-parallel groups	NA	
46	2017	2017	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Gizelle Baker, John Magnette, Patrick Picavet, Rolf Weitkunat	PMI	Tobacco	Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents with the THS 2.1	YES	YES	NO	Clinical trial	Randomized, open-label, two-parallel groups	NA	
46	2017	2017	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Gizelle Baker, John Magnette, Patrick Picavet, Rolf Weitkunat	PMI	Tobacco	Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents with the THS 2.1	YES	YES	NO	Clinical trial	Randomized, open-label, two-parallel groups	NA	
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinment and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA	
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinment and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA	
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinment and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA	
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinment and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA	
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinment and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA	
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinment and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA	
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinment and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA	
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinment and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA	
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinment and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA	

20	2018	2018	article	Research	Japan	Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	sequential confinement and ambulatory settings	NA
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA
48	2018	2018	Research article	Nicotine & Tobacco Research	Switzerland Japan	Frank Lüdicke, Patrick Picavet, Gizelle Baker, Christelle Haziza, Valerie Poux, Nicola Lama, Rof Weitkunat	PMI	Tobacco	Effects of Switching to the THS 2.2 Menthol, Smoking Abstinence, or Continued Cigarette Smoking on Biomarkers of Exposure: A Randomized, Controlled, Open-Label, Multicenter Study in Sequential Confinement and Ambulatory Settings (Part 1)	YES	YES	YES	Clinical trial	Randomized, controlled, open label, multicenter study in sequential confinement and ambulatory settings	NA
32	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Evaluation of the Tobacco Heating System 2.2. Part8_5-Day randomized reduced exposure clinical study in Poland	NO	YES	NO	Clinical trial	Controlled, randomized, three-arm parallel, single-center study, open label, in confinement	NA
32	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Evaluation of the Tobacco Heating System 2.2. Part8_5-Day randomized reduced exposure clinical study in Poland	NO	YES	NO	Clinical trial	Controlled, randomized, three-arm parallel, single-center study, open label, in confinement	NA
32	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Evaluation of the Tobacco Heating System 2.2. Part8_5-Day randomized reduced exposure clinical study in Poland	NO	YES	NO	Clinical trial	Controlled, randomized, three-arm parallel, single-center study, open label, in confinement	NA
32	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Evaluation of the Tobacco Heating System 2.2. Part8_5-Day randomized reduced exposure clinical study in Poland	NO	YES	NO	Clinical trial	Controlled, randomized, three-arm parallel, single-center study, open label, in confinement	NA
32	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Evaluation of the Tobacco Heating System 2.2. Part8_5-Day randomized reduced exposure clinical study in Poland	NO	YES	NO	Clinical trial	Controlled, randomized, three-arm parallel, single-center study, open label, in confinement	NA
32	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Evaluation of the Tobacco Heating System 2.2. Part8_5-Day randomized reduced exposure clinical study in Poland	NO	YES	NO	Clinical trial	Controlled, randomized, three-arm parallel, single-center study, open label, in confinement	NA
31	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland Japan	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Assessment of the reduction in levels of exposure to HPHCs in Japanese subjects using a novel THS compared to conventional cigarettes and smoking abstinence. A randomized controlled study in confinement	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA
31	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland Japan	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Assessment of the reduction in levels of exposure to HPHCs in Japanese subjects using a novel THS compared to conventional cigarettes and smoking abstinence. A randomized controlled study in confinement	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA
31	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland Japan	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Assessment of the reduction in levels of exposure to HPHCs in Japanese subjects using a novel THS compared to conventional cigarettes and smoking abstinence. A randomized controlled study in	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA

						First Exposure			confinement							
31	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland Japan	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Assessment of the reduction in levels of exposure to HPHCs in Japanese subjects using a novel THS compared to conventional cigarettes and smoking abstinence_A randomized controlled study in confinement	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA	
31	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland Japan	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Assessment of the reduction in levels of exposure to HPHCs in Japanese subjects using a novel THS compared to conventional cigarettes and smoking abstinence_A randomized controlled study in confinement	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA	
3	2016	2016	Research article	Regulatory Toxicology and Pharmacology	Switzerland Japan	Christelle Haziza, Guillaume de La Bourdonnaye, Dimitra Skiada, Jacek Ancerewicz, Gizelle Baker, Patrick Picavet, Frank Lüdicke	PMI	Tobacco	Assessment of the reduction in levels of exposure to HPHCs in Japanese subjects using a novel THS compared to conventional cigarettes and smoking abstinence_A randomized controlled study in confinement	YES	YES	YES	Clinical trial	Controlled, randomized, three-arm parallel, single-center study in confinement	NA	
47	2016	2016	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Christelle Haziza, Rolf Weitkunat, John Magnette	PMI	Tobacco	Evaluation of biomarkers of exposure in Smokers Switching to a Carbon-Heated Tobacco Product: A Controlled, Randomized, Open-Label 5-Day Exposure Study	YES	Yes	YES	Clinical trial	Randomized, open-label, three-arm, parallel-group, single-center, short-term study in confinement	NA	
47	2016	2016	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Christelle Haziza, Rolf Weitkunat, John Magnette	PMI	Tobacco	Evaluation of biomarkers of exposure in Smokers Switching to a Carbon-Heated Tobacco Product: A Controlled, Randomized, Open-Label 5-Day Exposure Study	YES	Yes	YES	Clinical trial	Randomized, open-label, three-arm, parallel-group, single-center, short-term study in confinement	NA	
47	2016	2016	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Christelle Haziza, Rolf Weitkunat, John Magnette	PMI	Tobacco	Evaluation of biomarkers of exposure in Smokers Switching to a Carbon-Heated Tobacco Product: A Controlled, Randomized, Open-Label 5-Day Exposure Study	YES	Yes	YES	Clinical trial	Randomized, open-label, three-arm, parallel-group, single-center, short-term study in confinement	NA	
47	2016	2016	Research article	Nicotine & Tobacco Research	Switzerland	Frank Lüdicke, Christelle Haziza, Rolf Weitkunat, John Magnette	PMI	Tobacco	Evaluation of biomarkers of exposure in Smokers Switching to a Carbon-Heated Tobacco Product: A Controlled, Randomized, Open-Label 5-Day Exposure Study	YES	Yes	YES	Clinical trial	Randomized, open-label, three-arm, parallel-group, single-center, short-term study in confinement	NA	
4	2015	2015	Research article	Inhalation Toxicology	USA	Appleton, S., Liu J., Lipowicz, P.J. and Mohamadi Sarkar	Altria	Tobacco	Effect of cigarette design on biomarkers of exposure, puffing topography and respiratory parameters	YES	YES	YES	Clinical trial	Randomized, controlled, double-blinded	NA	
4	2015	2015	Research article	Inhalation Toxicology	USA	Appleton, S., Liu J., Lipowicz, P.J. and Mohamadi Sarkar	Altria	Tobacco	Effect of cigarette design on biomarkers of exposure, puffing topography and respiratory parameters	YES	YES	YES	Clinical trial	Randomized, controlled, double-blinded	NA	
4	2015	2015	Research article	Inhalation Toxicology	USA	Appleton, S., Liu J., Lipowicz, P.J. and Mohamadi Sarkar	Altria	Tobacco	Effect of cigarette design on biomarkers of exposure, puffing topography and respiratory parameters	YES	YES	YES	Clinical trial	Randomized, controlled, double-blinded	NA	
4	2015	2015	Research article	Inhalation Toxicology	USA	Appleton, S., Liu J., Lipowicz, P.J. and Mohamadi Sarkar	Altria	Tobacco	Effect of cigarette design on biomarkers of exposure, puffing topography and respiratory parameters	NO	YES	NO	Clinical trial	Randomized, controlled, double-blinded	NA	
4	2015	2015	Research article	Inhalation Toxicology	USA	Appleton, S., Liu J., Lipowicz, P.J. and Mohamadi Sarkar	Altria	Tobacco	Effect of cigarette design on biomarkers of exposure, puffing topography and respiratory parameters	NO	YES	NO	Clinical trial	Randomized, controlled, double-blinded	NA	

82	2015	2015	Meeting abstract	Abstract EUROTOX -	USA	Logan Theophilus, Christopher Coggins, Peter Chen, Eckhardt Schmidt, Michael Borgerding	Academia	Other	Magnitudes of biomarker reductions in response to controlled reductions in cigarettes smoked per day: A one-week clinical confinement study	NO	NO	NO	NA	NA	NA
96	2013	2013	Research article	Respiration	Brazil	R. Fagundes Xavier, D. Ramos, J. Tiyaki Ito, F.M. Machado Rodrigues, G. Navarro Bertolini, M. Macchione, A. Choqueta de Toledo, E.M. Cipulo Ramos	Academia	Other	Effects of Cigarette Smoking Intensity on the Mucociliary Clearance of Active Smokers	NO	YES	NO	Smoking cessation program	Inclusion criteria	NA
96	2013	2013	Research article	Respiration	Brazil	R. Fagundes Xavier, D. Ramos, J. Tiyaki Ito, F.M. Machado Rodrigues, G. Navarro Bertolini, M. Macchione, A. Choqueta de Toledo, E.M. Cipulo Ramos	Academia	Other	Effects of Cigarette Smoking Intensity on the Mucociliary Clearance of Active Smokers	NO	YES	NO	Smoking cessation program	Inclusion criteria	NA
96	2013	2013	Research article	Respiration	Brazil	R. Fagundes Xavier, D. Ramos, J. Tiyaki Ito, F.M. Machado Rodrigues, G. Navarro Bertolini, M. Macchione, A. Choqueta de Toledo, E.M. Cipulo Ramos	Academia	Other	Effects of Cigarette Smoking Intensity on the Mucociliary Clearance of Active Smokers	NO	YES	NO	Smoking cessation program	Inclusion criteria	NA
96	2013	2013	Research article	Respiration	Brazil	R. Fagundes Xavier, D. Ramos, J. Tiyaki Ito, F.M. Machado Rodrigues, G. Navarro Bertolini, M. Macchione, A. Choqueta de Toledo, E.M. Cipulo Ramos	Academia	Other	Effects of Cigarette Smoking Intensity on the Mucociliary Clearance of Active Smokers	NO	YES	NO	Smoking cessation program	Inclusion criteria	NA
90	2013	2013	Research article	South African Medical journal	South Africa	S R van Staden, M Groenewaldl, R Engelbrecht: P J Becker; L T Hazelhurst	Academia	Other	Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes	YES	YES	YES	Single group switching to e-cigs	NA	NA
90	2013	2013	Research article	South African Medical journal	South Africa	S R van Staden, M Groenewaldl, R Engelbrecht: P J Becker; L T Hazelhurst	Academia	Other	Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes	YES	YES	YES	Single group switching to e-cigs	NA	NA
90	2013	2013	Research article	South African Medical journal	South Africa	S R van Staden, M Groenewaldl, R Engelbrecht: P J Becker; L T Hazelhurst	Academia	Other	Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes	YES	YES	YES	Single group switching to e-cigs	NA	NA
90	2013	2013	Research article	South African Medical journal	South Africa	S R van Staden, M Groenewaldl, R Engelbrecht: P J Becker; L T Hazelhurst	Academia	Other	Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes	YES	YES	YES	Single group switching to e-cigs	NA	NA
62	2008	2008	Research article	The Journal of Clinical Pharmacology	NA	Hans J. Roethig, Shixia Feng, Qiwei Liang, Jianmin Liu, William A. Rees, Barbara K. Zedler	Other	Other	A 12-Month, Randomized, Controlled Study to Evaluate Exposure and Cardiovascular Risk Factors in Adult Smokers Switching From Conventional Cigarettes to a Second-Generation Electrically Heated Cigarette Smoking System	YES	NO	NO	NA	NA	NA
73	2012	2012	Research article	Sunsari Technical College Journal	Nepal	Shah BK, Nepal AK, Agrawal M, Sinha AK	Academia	Other	The effects of cigarette smoking on hemoglobin levels compared between smokers and non smokers	NO	YES	NO	Cross-sectional comparative study	NA	NA
73	2012	2012	Research article	Sunsari Technical College Journal	Nepal	Shah BK, Nepal AK, Agrawal M, Sinha AK	Academia	Other	The effects of cigarette smoking on hemoglobin levels compared between smokers and non smokers	NO	YES	NO	Cross-sectional comparative study	NA	NA
87	2012	2012	Research article	Regulatory Toxicology and	UK	Anthony R.Tricker, Adrian J. Stewart, Claire Martin Leroy, Dirk	Consulting	Mixed	Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System: Results of a	YES	YES	YES	Randomized, controlled, open-label, parallel	NA	NA

20/48

19	2010	2011	Research article	Nicotine & Tobacco Research	USA/Lebanon	Caroline O. Cobb, Alan Shihadeh, Michael F. Weaver, Thomas Eissenberg	Academia	Other	Waterpipe Tobacco Smoking and Cigarette Smoking: A Direct Comparison of Toxicant Exposure and Subjective Effects	NO	YES	NO	Counter-balanced session	NA	NA
19	2010	2011	Research article	Nicotine & Tobacco Research	USA/Lebanon	Caroline O. Cobb, Alan Shihadeh, Michael F. Weaver, Thomas Eissenberg	Academia	Other	Waterpipe Tobacco Smoking and Cigarette Smoking: A Direct Comparison of Toxicant Exposure and Subjective Effects	NO	YES	NO	Counter-balanced session	NA	NA
68	2010	2010	Research article	Nicotine & Tobacco Research	USA	Mohamadi Sarkar, Jianmin Liu, Tamara Koval, Jingzhu Wang, Shixia Feng, Richard Serafin, Yan Jin, Yuli Xie, Kirk Newland, & Hans J. Roethig	Altria	Tobacco	Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro Snus	YES	YES	YES	Randomized, controlled, open-label, parallel-group, short-term study	Stratified by number of cigarettes	NA
68	2010	2010	Research article	Nicotine & Tobacco Research	USA	Mohamadi Sarkar, Jianmin Liu, Tamara Koval, Jingzhu Wang, Shixia Feng, Richard Serafin, Yan Jin, Yuli Xie, Kirk Newland, & Hans J. Roethig	Altria	Tobacco	Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro Snus	YES	YES	YES	Randomized, controlled, open-label, parallel-group, short-term study	Stratified by number of cigarettes	NA
68	2010	2010	Research article	Nicotine & Tobacco Research	USA	Mohamadi Sarkar, Jianmin Liu, Tamara Koval, Jingzhu Wang, Shixia Feng, Richard Serafin, Yan Jin, Yuli Xie, Kirk Newland, & Hans J. Roethig	Altria	Tobacco	Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro Snus	YES	YES	YES	Randomized, controlled, open-label, parallel-group, short-term study	Stratified by number of cigarettes	NA
68	2010	2010	Research article	Nicotine & Tobacco Research	USA	Mohamadi Sarkar, Jianmin Liu, Tamara Koval, Jingzhu Wang, Shixia Feng, Richard Serafin, Yan Jin, Yuli Xie, Kirk Newland, & Hans J. Roethig	Altria	Tobacco	Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro Snus	YES	YES	YES	Randomized, controlled, open-label, parallel-group, short-term study	Stratified by number of cigarettes	NA
68	2010	2010	Research article	Nicotine & Tobacco Research	USA	Mohamadi Sarkar, Jianmin Liu, Tamara Koval, Jingzhu Wang, Shixia Feng, Richard Serafin, Yan Jin, Yuli Xie, Kirk Newland, & Hans J. Roethig	Altria	Tobacco	Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro Snus	YES	YES	YES	Randomized, controlled, open-label, parallel-group, short-term study	Stratified by number of cigarettes	NA
68	2010	2010	Research article	Nicotine & Tobacco Research	USA	Mohamadi Sarkar, Jianmin Liu, Tamara Koval, Jingzhu Wang, Shixia Feng, Richard Serafin, Yan Jin, Yuli Xie, Kirk Newland, & Hans J. Roethig	Altria	Tobacco	Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro Snus	YES	YES	YES	Randomized, controlled, open-label, parallel-group, short-term study	Stratified by number of cigarettes	NA
68	2010	2010	Research article	Nicotine & Tobacco Research	USA	Mohamadi Sarkar, Jianmin Liu, Tamara Koval, Jingzhu Wang, Shixia Feng, Richard Serafin, Yan Jin, Yuli Xie, Kirk Newland, & Hans J. Roethig	Altria	Tobacco	Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro Snus	YES	YES	YES	Randomized, controlled, open-label, parallel-group, short-term study	Stratified by number of cigarettes	NA
68	2010	2010	Research article	Nicotine & Tobacco Research	USA	Mohamadi Sarkar, Jianmin Liu, Tamara Koval, Jingzhu Wang, Shixia Feng, Richard Serafin, Yan Jin, Yuli Xie, Kirk Newland, & Hans J. Roethig	Altria	Tobacco	Evaluation of biomarkers of exposure in adult cigarette smokers using Marlboro Snus	YES	YES	YES	Randomized, controlled, open-label, parallel-group, short-term study	Stratified by number of cigarettes	NA
89	2010	2010	Research article	Regulatory Toxicology and Pharmacology	South Africa	Unverdorben, M., Mostert, A., Munjal, S., van der Bijl, A., Potgieter, L., Venter, C., and Liang Q.	Consulting Altria	Mixed	Acute effects of cigarette smoking on pulmonary function	YES	YES	YES	Randomized three-eriod cross-over design	Single-blind	NA
89	2010	2010	Research article	Regulatory Toxicology and Pharmacology	South Africa	Unverdorben, M., Mostert, A., Munjal, S., van der Bijl, A., Potgieter, L., Venter, C., and Liang Q.	Consulting Altria	Mixed	Acute effects of cigarette smoking on pulmonary function	YES	YES	YES	Randomized three-eriod cross-over design	Single-blind	NA
						Unverdorben, M., Mostert, A., Munjal, S., van der Bijl, A., Potgieter, L., Venter, C., and Liang Q.									

89	2010	2010	Research article	Regulatory Toxicology and Pharmacology	South Africa	Muister L., A., Munjal, S., van der Bijl, A., Potgieter, L., Venter, C., and Liang Q.	Consulting Altria	Mixed	Acute effects of cigarette smoking on pulmonary function	YES	YES	YES	Randomized three-eriod cross-over design	Single-blind	NA
93	2010	2010	Research article	Regulatory Toxicology and Pharmacology	USA	Wang, J., Roethig, H.J., Appleton, S., Werley, M., Muhammad-Kah, R. and Paul Mendes	Altria	Tobacco	The effect of menthol containing cigarettes on adult smokers exposure to nicotine and carbon monoxide	YES	YES	NO	Cross-functional, observational, ambulatory, multi-centered study	Stratified by gender, age, and BMI	NA
93	2010	2010	Research article	Regulatory Toxicology and Pharmacology	USA	Wang, J., Roethig, H.J., Appleton, S., Werley, M., Muhammad-Kah, R. and Paul Mendes	Altria	Tobacco	The effect of menthol containing cigarettes on adult smokers exposure to nicotine and carbon monoxide	YES	YES	NO	Cross-functional, observational, ambulatory, multi-centered study	Stratified by gender, age, and BMI	NA
93	2010	2010	Research article	Regulatory Toxicology and Pharmacology	USA	Wang, J., Roethig, H.J., Appleton, S., Werley, M., Muhammad-Kah, R. and Paul Mendes	Altria	Tobacco	The effect of menthol containing cigarettes on adult smokers exposure to nicotine and carbon monoxide	YES	YES	YES	Cross-functional, observational, ambulatory, multi-centered study	Stratified by gender, age, and BMI	NA
93	2010	2010	Research article	Regulatory Toxicology and Pharmacology	USA	Wang, J., Roethig, H.J., Appleton, S., Werley, M., Muhammad-Kah, R. and Paul Mendes	Altria	Tobacco	The effect of menthol containing cigarettes on adult smokers exposure to nicotine and carbon monoxide	YES	YES	NO	Cross-functional, observational, ambulatory, multi-centered study	Stratified by gender, age, and BMI	NA
93	2010	2010	Research article	Regulatory Toxicology and Pharmacology	USA	Wang, J., Roethig, H.J., Appleton, S., Werley, M., Muhammad-Kah, R. and Paul Mendes	Altria	Tobacco	The effect of menthol containing cigarettes on adult smokers exposure to nicotine and carbon monoxide	YES	YES	NO	Cross-functional, observational, ambulatory, multi-centered study	Stratified by gender, age, and BMI	NA
93	2010	2010	Research article	Regulatory Toxicology and Pharmacology	USA	Wang, J., Roethig, H.J., Appleton, S., Werley, M., Muhammad-Kah, R. and Paul Mendes	Altria	Tobacco	The effect of menthol containing cigarettes on adult smokers exposure to nicotine and carbon monoxide	YES	YES	YES	Cross-functional, observational, ambulatory, multi-centered study	Stratified by gender, age, and BMI	NA
83	2010	2010	Research article	South African Medical journal	South Africa	Ansa Theron, Cedric Schultz, James A Ker, Nadia Falzone	Academia	Other	Carboxyhaemoglobin levels in water-pipe and cigarette smokers	NO	YES	NO	Self-reported CC smokers	Grouped by smoking preference	NA
83	2010	2010	Research article	South African Medical journal	South Africa	Ansa Theron, Cedric Schultz, James A Ker, Nadia Falzone	Academia	Other	Carboxyhaemoglobin levels in water-pipe and cigarette smokers	NO	YES	NO	Self-reported CC smokers	Grouped by smoking preference	NA
83	2010	2010	Research article	South African Medical journal	South Africa	Ansa Theron, Cedric Schultz, James A Ker, Nadia Falzone	Academia	Other	Carboxyhaemoglobin levels in water-pipe and cigarette smokers	YES	YES	YES	Self-reported CC smokers	Grouped by smoking preference	NA
83	2010	2010	Research article	South African Medical journal	South Africa	Ansa Theron, Cedric Schultz, James A Ker, Nadia Falzone	Academia	Other	Carboxyhaemoglobin levels in water-pipe and cigarette smokers	YES	YES	YES	Self-reported CC smokers	Grouped by smoking preference	NA
76	2009	2009	Research article	Journal of Surgical research	Denmark	Lars Tue Sorensen, Stig Jorgensen, Lars J. Petersen, Ulla Hemmingsen, Jens Bulow, Steffen Loft, Finn Gottrup	Academia	Other	Acute Effects of Nicotine and Smoking on Blood Flow, Tissue Oxygen, and Aerobe Metabolism of the Skin and Subcutis	NO	YES	NO	Single group Intermittent sprint test	Grouped by smoking preference	NA
76	2009	2009	Research article	Journal of Surgical research	Denmark	Lars Tue Sorensen, Stig Jorgensen, Lars J. Petersen, Ulla Hemmingsen, Jens Bulow, Steffen Loft, Finn Gottrup	Academia	Other	Acute Effects of Nicotine and Smoking on Blood Flow, Tissue Oxygen, and Aerobe Metabolism of the Skin and Subcutis	NO	YES	NO	Single group Intermittent sprint test	Grouped by smoking preference	NA
76	2009	2009	Research article	Journal of Surgical research	Denmark	Lars Tue Sorensen, Stig Jorgensen, Lars J. Petersen, Ulla Hemmingsen, Jens Bulow, Steffen Loft, Finn Gottrup	Academia	Other	Acute Effects of Nicotine and Smoking on Blood Flow, Tissue Oxygen, and Aerobe Metabolism of the Skin and Subcutis	NO	YES	NO	Single group Intermittent sprint test	Grouped by smoking preference	NA
76	2009	2009	Research article	Journal of Surgical research	Denmark	Lars Tue Sorensen, Stig Jorgensen, Lars J. Petersen, Ulla Hemmingsen, Jens Bulow, Steffen Loft, Finn Gottrup	Academia	Other	Acute Effects of Nicotine and Smoking on Blood Flow, Tissue Oxygen, and Aerobe Metabolism of the Skin and Subcutis	NO	YES	NO	Single group Intermittent sprint test	Grouped by smoking preference	NA
						Anna-Maja Aberg, Birgitta Nilsson									

1	2009	2009	Research article	Transfusion	Sweden	Sojka, Ola Winso, Pernilla Abrahamsson, Goran Johansson, Jan Erik Larsson	Academia	Other	Carbon monoxide concentration in donated blood: relation to cigarette smoking and other sources	NO	YES	NO	Donated blood?	NA	NA
53	2009	2009	Research article	Regulatory Toxicology and Pharmacology	USA	Paul Mendes, Qiwei Liang, Kimberly Frost-Pineda, Sagar Munjal, Ruediger-A. Walk, Hans J. Roethig	Altria	Tobacco	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US	YES	YES	NO	Stratified, cross-sectional, observational, multi-center design	Based on cigarette smoking status	NA
53	2009	2009	Research article	Regulatory Toxicology and Pharmacology	USA	Paul Mendes, Qiwei Liang, Kimberly Frost-Pineda, Sagar Munjal, Ruediger-A. Walk, Hans J. Roethig	Altria	Tobacco	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US	YES	YES	YES	Stratified, cross-sectional, observational, multi-center design	Based on cigarette smoking status	NA
53	2009	2009	Research article	Regulatory Toxicology and Pharmacology	USA	Paul Mendes, Qiwei Liang, Kimberly Frost-Pineda, Sagar Munjal, Ruediger-A. Walk, Hans J. Roethig	Altria	Tobacco	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US	YES	YES	YES	Stratified, cross-sectional, observational, multi-center design	Based on cigarette smoking status	NA
53	2009	2009	Research article	Regulatory Toxicology and Pharmacology	USA	Paul Mendes, Qiwei Liang, Kimberly Frost-Pineda, Sagar Munjal, Ruediger-A. Walk, Hans J. Roethig	Altria	Tobacco	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US	YES	YES	YES	Stratified, cross-sectional, observational, multi-center design	Based on cigarette smoking status	NA
53	2009	2009	Research article	Regulatory Toxicology and Pharmacology	USA	Paul Mendes, Qiwei Liang, Kimberly Frost-Pineda, Sagar Munjal, Ruediger-A. Walk, Hans J. Roethig	Altria	Tobacco	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US	YES	YES	YES	Stratified, cross-sectional, observational, multi-center design	Based on cigarette smoking status	NA
53	2009	2009	Research article	Regulatory Toxicology and Pharmacology	USA	Paul Mendes, Qiwei Liang, Kimberly Frost-Pineda, Sagar Munjal, Ruediger-A. Walk, Hans J. Roethig	Altria	Tobacco	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US	YES	YES	YES	Stratified, cross-sectional, observational, multi-center design	Based on cigarette smoking status	NA
63	2009	2009	Research article	Nicotine & Tobacco Research	USA	Hans J Roethig, Sagar Munjal, Shixia Feng, Qiwei Liang, Mohamadi Sarkar, Ruediger-A Walk, Paul Mendes	Altria	Tobacco	Population estimates for biomarkers of exposure to cigarette smoke in adult US cigarette smokers	YES	YES	YES	Stratified, cross-sectional, observational, multi-center design	Based on cigarette smoking status	NA
63	2009	2009	Research article	Nicotine & Tobacco Research	USA	Hans J Roethig, Sagar Munjal, Shixia Feng, Qiwei Liang, Mohamadi Sarkar, Ruediger-A Walk, Paul Mendes	Altria	Tobacco	Population estimates for biomarkers of exposure to cigarette smoke in adult US cigarette smokers	YES	YES	YES	Stratified, cross-sectional, observational, multi-center design	Based on cigarette smoking status	NA
42	2008	2008	Research article	Clinical and Investigative Medicine	Taiwan	Chien-Min Kung, Hai-Lung Wang, Zu-Lin Tseng	Academia	Other	Cigarette smoking exacerbates health problems in young men	YES	YES	NO	NA	NA	NA
42	2008	2008	Research article	Clinical and Investigative Medicine	Taiwan	Chien-Min Kung, Hai-Lung Wang, Zu-Lin Tseng	Academia	Other	Cigarette smoking exacerbates health problems in young men	YES	YES	YES	NA	NA	NA
42	2008	2008	Research article	Clinical and Investigative Medicine	Taiwan	Chien-Min Kung, Hai-Lung Wang, Zu-Lin Tseng	Academia	Other	Cigarette smoking exacerbates health problems in young men	YES	YES	YES	NA	NA	NA
66	2018	2018	Research article	Nicotine & Tobacco Research	USA	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	YES	YES	YES	Clinical study	parallel group study	NA
66	2018	2018	Research article	Nicotine & Tobacco Research	USA	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	YES	YES	YES	Clinical study	parallel group study	NA
66	2018	2018	Research article	Nicotine & Tobacco Research	USA	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	YES	YES	YES	Clinical study	parallel group study	NA
66	2018	2018	Research article	Nicotine & Tobacco Research	USA	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	YES	YES	YES	Clinical study	parallel group study	NA
66	2018	2018	Research article	Nicotine & Tobacco Research	USA	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	YES	YES	YES	Clinical study	parallel group study	NA

66	2018	2018	Research article	Nicotine & Tobacco Research	USA	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	YES	YES	YES	Clinical study	parallel group study	NA
66	2018	2018	Research article	Nicotine & Tobacco Research	USA	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	YES	YES	YES	Clinical study	parallel group study	NA
66	2018	2018	Research article	Nicotine & Tobacco Research	USA	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	YES	YES	YES	Clinical study	parallel group study	NA
57	2020	2020	Research article	Nicotine & Tobacco Research	USA	Oliveri D, Liang Q, Sarkar M	Altria	Tobacco	Real-World Evidence of Differences in Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers	YES	YES	YES	Clinical study	cross-functional observational study	NA
57	2020	2020	Research article	Nicotine & Tobacco Research	USA	Oliveri D, Liang Q, Sarkar M	Altria	Tobacco	Real-World Evidence of Differences in Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers	YES	YES	YES	Clinical study	cross-functional observational study	NA
84	2020	2020	Research article	Sci Rep.	USA	Tran CT, Bosilkovska M, de La Bourdonnaye G, Blanc N, Haziza C	PMI	Tobacco	Reduced levels of biomarkers of exposure in smokers switching to the Carbon-Heated Tobacco Product 1.0: a controlled, randomized, open-label 5-day exposure trial Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers	YES	YES	YES	Clinical study	controlled, randomized, open-label, two-arm parallel group, single-center confinement study	NA
84	2020	2020	Research article	Sci Rep.	USA	Tran CT, Bosilkovska M, de La Bourdonnaye G, Blanc N, Haziza C	PMI	Tobacco	Reduced levels of biomarkers of exposure in smokers switching to the Carbon-Heated Tobacco Product 1.0: a controlled, randomized, open-label 5-day exposure trial Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers	YES	YES	YES	Clinical study	controlled, randomized, open-label, two-arm parallel group, single-center confinement study	NA
84	2020	2020	Research article	Sci Rep.	USA	Tran CT, Bosilkovska M, de La Bourdonnaye G, Blanc N, Haziza C	PMI	Tobacco	Reduced levels of biomarkers of exposure in smokers switching to the Carbon-Heated Tobacco Product 1.0: a controlled, randomized, open-label 5-day exposure trial Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers	YES	YES	YES	Clinical study	controlled, randomized, open-label, two-arm parallel group, single-center confinement study	NA
84	2020	2020	Research article	Sci Rep.	USA	Tran CT, Bosilkovska M, de La Bourdonnaye G, Blanc N, Haziza C	PMI	Tobacco	Reduced levels of biomarkers of exposure in smokers switching to the Carbon-Heated Tobacco Product 1.0: a controlled, randomized, open-label 5-day exposure trial Biomarkers of Exposure to Select Harmful and Potentially Harmful Constituents and Biomarkers of Potential Harm Between Adult E-Vapor Users and Adult Cigarette Smokers	YES	YES	YES	Clinical study	controlled, randomized, open-label, two-arm parallel group, single-center confinement study	NA

Supplemental Table 2 NEQ: Complete list of studies included in the analysis; summary with study types

Ref																
-----	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**** ID	PUB_Years0	PUB_Years	PUB_Type	PUB_Name	PUB_Country	PUB_Authors	PUB_Company	PUB_Code_comp	PUB_Title	PUB_relevant	PUB_Available	PUB_use	STUD_Type	STUD_Method	STUD_Assessment	STUD
12	2016	2016	Article	Practical Laboratory Medicine	Germany	Camacho O.M., Sommarström J., Prasad K., Cunningham A	BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure	YES	YES	YES	Observational clinical study	No. All subjects were smokers	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
100	2018	2018	Article	Reg Toxicology and Pharmacology	Japan	Yuki D., Takeshige Y., Nakaya K., Futamura Y.	Japan Tobacco	Tobacco	Assessment of the exposure to harmful and potentially harmful constituents in healthy Japanese	Yes	Yes	YES	Clinical study	Yes	NA	NA
37	2009	2009	Article	Cancer Epidemiol Biomarkers Prev	US	Heck, J. D	Lorillard Tobacco Company	Tobacco	Smokers of Menthol and Nonmenthol Cigarettes Exhibit Similar Levels of Biomarkers of Smoke Exposure	Yes	Yes	NO	Clinical study	No	NA	NA
37	2009	2009	Article	Cancer Epidemiol Biomarkers Prev	US	Heck, J. D	Lorillard Tobacco Company	Tobacco	Smokers of Menthol and Nonmenthol Cigarettes Exhibit Similar Levels of Biomarkers of Smoke	Yes	Yes	NO	Clinical study	No	NA	NA

									Exposure							
58	2016	2016	Article	Clin Chem Lab Med	US	Prasad G.L., Jones B.A., Chen P., Gregg E.O.	Reynolds Tobacco	Tobacco	A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers	Yes	Yes	YES	Clinical study	No	NA	NA
58	2016	2016	Article	Clin Chem Lab Med	US	Prasad G.L., Jones B.A., Chen P., Gregg E.O.	Reynolds Tobacco	Tobacco	A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers	Yes	Yes	YES	Clinical study	No	NA	NA
58	2016	2016	Article	Clin Chem Lab Med	US	Prasad G.L., Jones B.A., Chen P., Gregg E.O.	Reynolds Tobacco	Tobacco	A cross-sectional study of biomarkers of exposure and effect in smokers and moist snuff consumers	Yes	Yes	YES	Clinical study	No	NA	NA
45	2009	2009	Article	Clin Chem Lab Med	UK	Lowe F.J., Gregg E.O., McEwan M.	BAT	Tobacco	Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers	Yes	Yes	YES	Clinical study	No	NA	NA
45	2009	2009	Article	Clin Chem Lab Med	UK	Lowe F.J., Gregg E.O., McEwan M.	BAT	Tobacco	Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers	Yes	Yes	YES	Clinical study	No	NA	NA
45	2009	2009	Article	Clin Chem Lab Med	UK	Lowe F.J., Gregg E.O., McEwan M.	BAT	Tobacco	Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers	Yes	Yes	YES	Clinical study	No	NA	NA
45	2009	2009	Article	Clin Chem Lab Med	UK	Lowe F.J., Gregg E.O., McEwan M.	BAT	Tobacco	Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers	Yes	Yes	YES	Clinical study	No	NA	NA
62	2008	2008	Article	J clinical Pharmacology	US	Roethig H.J., Feng X., Liang Q., Liu J., Rees W.A., Zedler B.K	PMI	Tobacco	A 12-Month, Randomized, Controlled Study to Evaluate Exposure and Cardiovascular Risk Factors in Adult Smokers Switching From Conventional Cigarettes to a Second-Generation Electrically Heated Cigarette Smoking System	Yes	Yes	YES	Clinical study	Yes	NA	NA
62	2008	2008	Article	J clinical Pharmacology	US	Roethig H.J., Feng X., Liang Q., Liu J., Rees W.A., Zedler B.K	PMI	Tobacco	A 12-Month, Randomized, Controlled Study to Evaluate Exposure and Cardiovascular Risk Factors in Adult Smokers Switching From Conventional Cigarettes to a Second-Generation Electrically Heated Cigarette Smoking System	Yes	Yes	YES	Clinical study	Yes	NA	NA
									A 12-Month, Randomized, Controlled							

62	2008	2008	Article	J clinical Pharmacology	US	Roethig H.J., Feng X., Liang O., Liu J., Rees W.A., Zedler B.K	PMI	Tobacco	Controlled Study to Evaluate Exposure and Cardiovascular Risk Factors in Adult Smokers Switching From Conventional Cigarettes to a Second- Generation Electrically Heated Cigarette Smoking System	Yes	Yes	YES	Clinical study	Yes	NA	NA
62	2008	2008	Article	J clinical Pharmacology	US	Roethig H.J., Feng X., Liang O., Liu J., Rees W.A., Zedler B.K	PMI	Tobacco	A 12-Month, Randomized, Controlled Study to Evaluate Exposure and Cardiovascular Risk Factors in Adult Smokers Switching From Conventional Cigarettes to a Second- Generation Electrically Heated Cigarette Smoking System	Yes	Yes	YES	Clinical study	Yes	NA	NA
63	2009	2009	Article	Nicotine & Tobacco Research	US	Roethig H.J., Munjai S., Feng S., Liang O., Sarkar M., Walk R.A., Mendes P.E.	Altria	Tobacco	Population estimates for biomarkers of exposure to cigarette smoke in adult US cigarette smokers	Yes	Yes	YES	Clinical study	Yes	Not reported	Not reported
63	2009	2009	Article	Nicotine & Tobacco Research	US	Roethig H.J., Munjai S., Feng S., Liang O., Sarkar M., Walk R.A., Mendes P.E.	Altria	Tobacco	Population estimates for biomarkers of exposure to cigarette smoke in adult US cigarette smokers	Yes	Yes	NO	Clinical study	Yes	Not reported	Not reported
70	2014	2014	Article	Biomarkers	UK	Scherer G., Newland K., Papadopoulos E., Minet E.	ABF/Celerion	Other	A correlation study applied to biomarkers of internal and effective dose for acrylonitrile and 4- aminobiphenyl in smokers	Yes	Yes	YES	Clinical study	No	NA	NA
70	2014	2014	Article	Biomarkers	UK	Scherer G., Newland K., Papadopoulos E., Minet E.	ABF/Celerion	Other	A correlation study applied to biomarkers of internal and effective dose for acrylonitrile and 4- aminobiphenyl in smokers	Yes	Yes	YES	Clinical study	No	NA	NA
70	2014	2014	Article	Biomarkers	UK	Scherer G., Newland K., Papadopoulos E., Minet E.	ABF/Celerion	Other	A correlation study applied to biomarkers of internal and effective dose for acrylonitrile and 4- aminobiphenyl in smokers	Yes	Yes	YES	Clinical study	No	NA	NA
70	2014	2014	Article	Biomarkers	UK	Scherer G., Newland K., Papadopoulos E., Minet E.	ABF/Celerion	Other	A correlation study applied to biomarkers of internal and effective dose for acrylonitrile and 4- aminobiphenyl in smokers	Yes	Yes	YES	Clinical study	No	NA	NA
54	2011	2011	Article	Regulatory Toxicology and Pharmacology	UK	Morin A., Shepperd C.J., Eldridge A.C., Poirier N., Voisine R.	Imperial	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of	Yes	Yes	YES	Clinical study	No	Not reported	Not reported

									exposure							
54	2011	2011	Article	Regulatory Toxicology and Pharmacology	UK	Morin A., Shepperd C.J., Eldridge A.C., Poirier N., Voisine R.	Imperial	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure	Yes	Yes	YES	Clinical study	No	Not reported	Not reported
54	2011	2011	Article	Regulatory Toxicology and Pharmacology	UK	Morin A., Shepperd C.J., Eldridge A.C., Poirier N., Voisine R.	Imperial	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure	Yes	Yes	YES	Clinical study	No	Not reported	Not reported
54	2011	2011	Article	Regulatory Toxicology and Pharmacology	UK	Morin A., Shepperd C.J., Eldridge A.C., Poirier N., Voisine R.	Imperial	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure	Yes	Yes	YES	Clinical study	No	Not reported	Not reported
66	2018	2018	Article	Nicotine & Tobacco Research	US	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	Yes	Yes	YES	Clinical study		parallel group study	Not reported
66	2018	2018	Article	Nicotine & Tobacco Research	US	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	Yes	Yes	YES	Clinical study	0	parallel group study	Not reported
66	2018	2018	Article	Nicotine & Tobacco Research	US	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	Yes	Yes	YES	Clinical study		parallel group study	Not reported
66	2018	2018	Article	Nicotine & Tobacco Research	US	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	Yes	Yes	NO	Clinical study	0	parallel group study	Not reported
66	2018	2018	Article	Nicotine & Tobacco Research	US	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	Yes	Yes	YES	Clinical study		parallel group study	Not reported
66	2018	2018	Article	Nicotine & Tobacco Research	US	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	Yes	Yes	YES	Clinical study	0	parallel group study	Not reported
66	2018	2018	Article	Nicotine & Tobacco Research	US	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	Yes	Yes	YES	Clinical study		parallel group study	Not reported
66	2018	2018	Article	Nicotine & Tobacco Research	US	Round E.K., Chen P., Taylor A.K., Schmidt E.	Raynolds Tobacco	Tobacco	Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum	Yes	Yes	NO	Clinical study	0	parallel group study	Not reported

									Cigarette or Nicotine Gum							
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg

									smokers following partial or complete substitution of cigarettes with electronic cigarettes							
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study	open-label forced-switch parallel arm study	Not rep	
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	NO	Clinical study	open-label forced-switch parallel arm study	Not rep	
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study	open-label forced-switch parallel arm study	Not rep	
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	NO	Clinical study	open-label forced-switch parallel arm study	Not rep	
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study	open-label forced-switch parallel arm study	Not rep	
									Reductions in biomarkers of exposure, impacts on							

21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	NO	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	YES	Clinical study		open-label forced-switch parallel arm study	Not reg
21	2016	2016	Article	BMC Public Health	US	D'Ruiz C., Graff D.W., Robinson E.	ITG Brands	Tobacco	Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes	Yes	Yes	NO	Clinical study		open-label forced-switch parallel arm study	Not reg

Supplemental Table 3 NNAL: Complete list of studies included in the analysis; summary with study types

Manuscript ID	PUB_Years	PUB_Type	PUB_Name	PUB_Country	PUB_Authors	PUB_Company	PUB_Code_comp	PUB_Title	PUB_relevant	PUB_Available	PUB_use	STUD_Type	STUD_Method	STUD_Assessment	STU
52	2020	Research article	Nicotine Tob Res	USA	Ellen Meier., Bruce R. Lindgren., Amanda Anderson, Sarah A. Reisinger, Kaila J. Norton, Joni Jensen, LoriStrayer, LauraDick, Mei-KuenTang, MenglanChen, StevenG.Carmella, StephenS.Hecht, Sharon E. Murphy, Jing Yang, Irina Stepanov, Richard J. O'Connor, Peter G. Shields, Dorothy K. Hatsukami		Other	A Randomized ClinicalTrial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure	YES	YES	YES	8-week multisite clinical study	randomized	single measure	not n
					Ellen Meier., Bruce R. Lindgren., Amanda Anderson, Sarah A. Reisinger, Kaila J. Norton, Joni			A Randomized							

52	2020	Research article	Nicotine Tob Res	USA	Jensen, LoriStrayer, LauraDick, Mei-KuenTang, MenglanChen, StevenG.Carmella, StephenS.Hecht, Sharon E. Murphy, Jing Yang, Irina Stepanov Richard J. O'Connor, Peter G. Shields, Dorothy K. Hatsukami	Other	ClinicalTrial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure	YES	YES	YES	8-week multisite clinical study	randomized	single measure	not n
52	2020	Research article	Nicotine Tob Res	USA	Ellen Meier,, Bruce R. Lindgren,, Amanda Anderson, Sarah A. Reisinger, Kaila J. Norton, Joni Jensen, LoriStrayer, LauraDick, Mei-KuenTang, MenglanChen, StevenG.Carmella, StephenS.Hecht, Sharon E. Murphy, Jing Yang, Irina Stepanov Richard J. O'Connor, Peter G. Shields, Dorothy K. Hatsukami	Other	A Randomized ClinicalTrial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure	YES	YES	YES	8-week multisite clinical study	randomized	single measure	not n
52	2020	Research article	Nicotine Tob Res	USA	Ellen Meier,, Bruce R. Lindgren,, Amanda Anderson, Sarah A. Reisinger, Kaila J. Norton, Joni Jensen, LoriStrayer, LauraDick, Mei-KuenTang, MenglanChen, StevenG.Carmella, StephenS.Hecht, Sharon E. Murphy, Jing Yang, Irina Stepanov Richard J. O'Connor, Peter G. Shields, Dorothy K. Hatsukami	Other	A Randomized ClinicalTrial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure	YES	YES	YES	8-week multisite clinical study	randomized	single measure	not n
52	2020	Research article	Nicotine Tob Res	USA	Ellen Meier,, Bruce R. Lindgren,, Amanda Anderson, Sarah A. Reisinger, Kaila J. Norton, Joni Jensen, LoriStrayer, LauraDick, Mei-KuenTang, MenglanChen, StevenG.Carmella, StephenS.Hecht, Sharon E. Murphy, Jing Yang, Irina Stepanov Richard J. O'Connor, Peter G. Shields, Dorothy K. Hatsukami	Other	A Randomized ClinicalTrial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure	YES	YES	YES	8-week multisite clinical study	randomized	single measure	not n
52	2020	Research article	Nicotine Tob Res	USA	Ellen Meier,, Bruce R. Lindgren,, Amanda Anderson, Sarah A. Reisinger, Kaila J. Norton, Joni Jensen, LoriStrayer, LauraDick, Mei-KuenTang, MenglanChen, StevenG.Carmella, StephenS.Hecht, Sharon E. Murphy, Jing Yang, Irina Stepanov Richard J. O'Connor, Peter G. Shields, Dorothy K. Hatsukami	Other	A Randomized ClinicalTrial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure	YES	YES	YES	8-week multisite clinical study	randomized	single measure	not n
52	2020	Research article	Nicotine Tob Res	USA	Ellen Meier,, Bruce R. Lindgren,, Amanda Anderson, Sarah A. Reisinger, Kaila J. Norton, Joni Jensen, LoriStrayer, LauraDick, Mei-KuenTang, MenglanChen, StevenG.Carmella, StephenS.Hecht, Sharon E. Murphy, Jing Yang, Irina Stepanov Richard J. O'Connor, Peter G. Shields, Dorothy K. Hatsukami	Other	A Randomized ClinicalTrial of Snus Examining the Effect of Complete Versus Partial Cigarette Substitution on Smoking-Related Behaviors, and Biomarkers of Exposure	YES	YES	YES	8-week multisite clinical study	randomized	single measure	not n
			Cancer		Wasserman EJ,		Comparison of Biomarkers of Tobacco Exposure between People							

94	2018		Epidemiol Biomarkers Prev.	USA	Reilly SM, Goel R, Foulds J, Richie JP Jr, Muscat JE.		Other	between Premium and Discount Brand Cigarette Smokers in the NHANES 2011-2012 Special Sample.	YES	YES	YES	Observational	NHANES special smoker sample		
94	2018		Cancer Epidemiol Biomarkers Prev.	USA	Wasserman EJ, Reilly SM, Goel R, Foulds J, Richie JP Jr, Muscat JE.		Other	Comparison of Biomarkers of Tobacco Exposure between Premium and Discount Brand Cigarette Smokers in the NHANES 2011-2012 Special Sample.	YES	YES	YES	Observational	NHANES special smoker sample		
59	2018		Nicotine Tob Res.	USA	Pulvers K, Emami AS, Nollen NL, Romero DR, Strong DR, Benowitz NL, Ahluwalia JS.	Academia, primarily CA Universities	Other	Tobacco Consumption and Toxicant Exposure of Cigarette Smokers Using Electronic Cigarettes.	YES	Yes	YES	Longitudinal switching study	not randomized		
25	2017		Nicotine Tob Res	Poland	Goniewicz ML, Gawron M, Smith DM, Peng M, Jacob P 3rd, Benowitz NL.	Roswell Park Cancer Institute, U of Silesia, UCSF	Other	Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study.	YES	Yes	YES	Longitudinal switching study	not randomized		not r
49	2016		Am J Physiol Lung Cell Mol Physiol.	USA	Martin EM, Clapp PW, Rebuli ME, Pawlak EA, Glista-Baker E, Benowitz NL, Fry RC, Jaspers I.	Academia, UNC, Chapel Hill, UCSF	Other	E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke.	YES	Yes	YES	Lab based	not randomized	Single measure	
49	2016		Am J Physiol Lung Cell Mol Physiol.	USA	Martin EM, Clapp PW, Rebuli ME, Pawlak EA, Glista-Baker E, Benowitz NL, Fry RC, Jaspers I.	Academia, UNC, Chapel Hill, UCSF	Other	E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke.	YES	Yes	YES	Lab based	not randomized	Single measure	
15	2016		Cancer Epidemiol Biomarkers Prev.	USA	Chen G, Luo S, Kozlovich S, Lazarus P.	Washington State University	Other	Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.	YES	Yes	YES	Analysis of urinary NNAL from two case control studies	not randomized		
15	2016		Cancer Epidemiol Biomarkers Prev.	USA	Chen G, Luo S, Kozlovich S, Lazarus P.	Washington State University	Other	Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.	YES	Yes	YES	Analysis of urinary NNAL from two case control studies	not randomized		
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	

								study.							
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	

12	2016		Pract Lab Med.	Germany	Camacho OM, Sommarström J, Prasad K, Cunningham A.	Industry BAT	Tobacco	Reference change values in concentrations of urinary and salivary biomarkers of exposure and mouth level exposure in individuals participating in an ambulatory smoking study.	YES	Yes	YES	Observational Study 10 sites (3.5 years)	not randomized	measured at 7 time points. Baseline and every 6 months	
99	2016		Cancer Prev Res (Phila).	USA	Yuan JM, Stepanov I, Murphy SE, Wang R, Allen S, Jensen J, Strayer L, Adams-Haduch J, Upadhyaya P, Le C, Kurzer MS, Nelson HH, Yu MC, Hatsukami D, Hecht SS.	Academia, Universities of Pittsburgh, Minnesota and Southern California	Other	Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers.	YES	Yes	YES	Randomized, placebo controlled, double-blind, crossover clinical trial		Visit 2	
99	2016		Cancer Prev Res (Phila).	USA	Yuan JM, Stepanov I, Murphy SE, Wang R, Allen S, Jensen J, Strayer L, Adams-Haduch J, Upadhyaya P, Le C, Kurzer MS, Nelson HH, Yu MC, Hatsukami D, Hecht SS.	Academia, Universities of Pittsburgh, Minnesota and Southern California	Other	Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers.	YES	Yes	YES	Randomized, placebo controlled, double-blind, crossover clinical trial		Visit 2	
99	2016		Cancer Prev Res (Phila).	USA	Yuan JM, Stepanov I, Murphy SE, Wang R, Allen S, Jensen J, Strayer L, Adams-Haduch J, Upadhyaya P, Le C, Kurzer MS, Nelson HH, Yu MC, Hatsukami D, Hecht SS.	Academia, Universities of Pittsburgh, Minnesota and Southern California	Other	Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers.	YES	Yes	YES	Randomized, placebo controlled, double-blind, crossover clinical trial		Visit 2	
95	2016		J Expo Sci Environ Epidemiol.	USA	Wei B, Blount BC, Xia B, Wang L.	Government, CDC	Other	Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012.	YES	Yes	YES	Analysis of samples collected in NHANES - note additional smoker values are reported by race and age ranges	not randomized		
95	2016		J Expo Sci Environ Epidemiol.	USA	Wei B, Blount BC, Xia B, Wang L.	Government, CDC	Other	Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012.	YES	Yes	YES	Analysis of samples collected in NHANES	not randomized		
95	2016		J Expo Sci Environ Epidemiol.	USA	Wei B, Blount BC, Xia B, Wang L.	Government, CDC	Other	Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012.	YES	Yes	YES	Analysis of samples collected in NHANES	not randomized		
95	2016		J Expo Sci Environ Epidemiol.	USA	Wei B, Blount BC, Xia B, Wang L.	Government, CDC	Other	Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012.	YES	Yes	YES	Analysis of samples collected in NHANES	not randomized		
95	2016		J Expo Sci Environ Epidemiol.	USA	Wei B, Blount BC, Xia B, Wang L.	Government, CDC	Other	Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012.	YES	Yes	YES	Analysis of samples collected in NHANES - note additional smoker values are reported by race and age ranges	not randomized		
95	2016		J Expo Sci Environ Epidemiol.	USA	Wei B, Blount BC, Xia B, Wang L.	Government, CDC	Other	Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012.	YES	Yes	YES	Analysis of samples collected in NHANES	not randomized		
95	2016		J Expo Sci Environ Epidemiol.	USA	Wei B, Blount BC, Xia B, Wang L.	Government, CDC	Other	Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012.	YES	Yes	YES	Analysis of samples collected in	not randomized		

								measured in US population: 2011-2012.				NHANES			
95	2016	J Expo Sci Environ Epidemiol.	USA	Wei B, Blount BC, Xia B, Wang L.	Government, CDC	Other		Assessing exposure to tobacco-specific carcinogen NNK using its urinary metabolite NNAL measured in US population: 2011-2012.	YES	Yes	YES	Analysis of samples collected in NHANES	not randomized		
20	2015	Nicotine Tob Res.	Canada	Czoli CD, Hammond D.	Academia University of Waterloo	Other		TSNA Exposure: Levels of NNAL Among Canadian Tobacco Users.	YES	Yes	YES	Secondary cross-sectional data analysis	not randomized		
97	2015	Clin Chem Lab Med.	Not reported	Yang JY, Ahn HK, Lee SW, Han YJ, Oh YJ, Velázquez-Armenta EY, Nava-Ocampo AA.		Other		Simple high-throughput analytical method using ultra-performance liquid chromatography coupled with tandem mass spectrometry to quantify total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in urine.	YES	YES	YES	Lab-based	not randomized		
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			
51	2014	Nicotine Tob Res.	USA	McKinney DL, Frost-Pineda K, Oldham MJ, Fisher MT, Wang J, Gogova M, Kobal G.	Industry ALCS	Tobacco		Cigarettes with different nicotine levels affect sensory perception and levels of biomarkers of exposure in adult smokers.	YES	Yes	YES	Double-blind Controlled Switching Study			

11	2013		Cancer Epidemiol Biomarkers Prev.	USA	Branstetter SA, Muscat JE.	Academia Penn State	Other	Time to first cigarette and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) levels in adult smokers; National Health and Nutrition Examination Survey (NHANES), 2007-2010.	YES	Yes	YES	Secondary cross-sectional data analysis			
11	2013		Cancer Epidemiol Biomarkers Prev.	USA	Branstetter SA, Muscat JE.	Academia Penn State	Other	Time to first cigarette and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) levels in adult smokers; National Health and Nutrition Examination Survey (NHANES), 2007-2010.	YES	Yes	YES	Secondary cross-sectional data analysis		Creatinine adjusted NNAL	
11	2013		Cancer Epidemiol Biomarkers Prev.	USA	Branstetter SA, Muscat JE.	Academia Penn State	Other	Time to first cigarette and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) levels in adult smokers; National Health and Nutrition Examination Survey (NHANES), 2007-2010.	YES	Yes	YES	Secondary cross-sectional data analysis			
11	2013		Cancer Epidemiol Biomarkers Prev.	USA	Branstetter SA, Muscat JE.	Academia Penn State	Other	Time to first cigarette and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) levels in adult smokers; National Health and Nutrition Examination Survey (NHANES), 2007-2010.	YES	Yes	YES	Secondary cross-sectional data analysis		Creatinine adjusted NNAL	
11	2013		Cancer Epidemiol Biomarkers Prev.	USA	Branstetter SA, Muscat JE.	Academia Penn State	Other	Time to first cigarette and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) levels in adult smokers; National Health and Nutrition Examination Survey (NHANES), 2007-2010.	YES	Yes	YES	Secondary cross-sectional data analysis			
60	2013		Nicotine Tob Res.	Egypt	Radwan G, Hecht SS, Carmella SG, Loffredo CA.	Cairo Dept. of Health, U of Minnesota, Georgetown University	Other	Tobacco-specific nitrosamine exposures in smokers and nonsmokers exposed to cigarette or waterpipe tobacco smoke.	YES	Yes	YES	Home interviews with survey and urine collection		Total NNAL	
64	2013			USA	Rostron B. 2013	Government, FDA	Other	NNAL exposure by race and Menthol Cigarette Use among U.S. smokers	YES	Yes	YES				
64	2013			USA	Rostron B. 2013	Government, FDA	Other	NNAL exposure by race and Menthol Cigarette Use among U.S. smokers	YES	Yes	YES				
41	2012		Head Neck	USA	Khariwala, S.S., Carmella, S.G., Stepanov, I., Fernandes, P., Lassig, A.A., Yueh, B., Hatsukami, D., Hecht, S.S.		Other	Elevated levels of 1-hydroxypyrene and N'-nitrosonornicotine in smokers with head and neck cancer: a matched control study.	YES	Yes	YES	Cross-sectional study of cigarette smokers who were head and neck squamous cell carcinoma cases		Total NNAL 10-mL urine	
41	2012		Head Neck	USA	Khariwala, S.S., Carmella, S.G., Stepanov, I., Fernandes, P., Lassig, A.A., Yueh, B., Hatsukami, D., Hecht, S.S.		Other	Elevated levels of 1-hydroxypyrene and N'-nitrosonornicotine in smokers with head and neck cancer: a matched control study.	YES	Yes	YES	Cross-sectional study of cigarette smokers who were head and neck squamous cell carcinoma cases		Total NNAL 10-mL urine	
81	2012		Int. J. Cancer 130, 1338-1346.	USA	Ter-Minassian, M., Asomaning, K., Zhao, Y., Chen, F., Su, L., Carmella, S.G., Lin, X., Hecht, S.S., Christiani, D.C., 2012.		Other	Genetic variability in the metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to 4-(methylnitrosamino)-1-(3-pyridyl)-1-	YES	Yes	YES	Cross-sectional study of current cigarette smokers		Total NNAL	

								butanol (NNAL).								
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
10	2012	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.	Academia UCSF	Other	Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.	YES	Yes	YES	RCT		Baseline, Week 14, Week 26	Com anal	
78	2012		Chem Res Toxicol.	USA, Poland	St Helen G, Goniewicz ML, Dempsey D, Wilson M, Jacob P 3rd, Benowitz NL.		Other	Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers.	YES	YES	YES	Clinical	not randomized			
78	2012		Chem Res Toxicol.	USA, Poland	St Helen G, Goniewicz ML, Dempsey D, Wilson M, Jacob P 3rd, Benowitz NL.		Other	Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers.	YES	YES	YES	Clinical	not randomized			
78	2012		Chem Res Toxicol.	USA, Poland	St Helen G, Goniewicz ML, Dempsey D, Wilson M, Jacob P 3rd, Benowitz NL.		Other	Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette	YES	YES	YES	Clinical	not randomized			

								SMOKERS.									
78	2012		Chem Res Toxicol.	USA, Poland	St Helen G, Goniiewicz ML, Dempsey D, Wilson M, Jacob P 3rd, Benowitz NL.		Other	Exposure and kinetics of polycyclic aromatic hydrocarbons (PAHs) in cigarette smokers.	YES	YES	YES	Clinical	not randomized				
98	2011	Research article	Cancer Res.	Shanghai, China	Yuan JM, Gao YT, Murphy SE, Carmella SG, Wang R, Zhong Y, Moy KA, Davis AB, Tao L, Chen M, Han S, Nelson HH, Yu MC, Hecht SS.		Other	Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers.	YES	Yes	YES	Analysis of Shanghai Cohort biosamples	Random selection of control smoker biospecimens				
98	2011	Research article	Cancer Res.	Shanghai, China	Yuan JM, Gao YT, Murphy SE, Carmella SG, Wang R, Zhong Y, Moy KA, Davis AB, Tao L, Chen M, Han S, Nelson HH, Yu MC, Hecht SS.		Other	Urinary levels of cigarette smoke constituent metabolites are prospectively associated with lung cancer development in smokers.	YES	Yes	YES	Analysis of Shanghai Cohort biosamples	Random selection of control smoker biospecimens				
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES	Yes	YES	Combined from review					
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Randomized trial					
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Randomized trial					
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Observational					
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Observational					
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Randomized trial					
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Observational					
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Dose-Ranging					
								The ratio of a urinary tobacco-									

91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Randomized trial			
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Randomized trial			
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Randomized trial			
91	2011	Review	Biomarkers.	USA	Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.	Academia, University of Minnesota	Other	The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.	YES?	Yes	NO	Randomized trial			
44	2011	Research article	Cancer Epidemiol Biomarkers Prev.	USA	Liu J, Liang Q, Frost-Pineda K, Muhammad-Kah R, Rimmer L, Roethig H, Mendes P, Sarkar M.	Industry ALCS	Tobacco	Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers.	YES	Yes	YES	Secondary cross-sectional data analysis	24 h Urine	Excl	anal
74	2011	Research Article	Regul Toxicol Pharmacol.	Germany	Shepperd CJ, Eldridge AC, Errington G, Dixon M.	Industry BAT	Tobacco	A study to evaluate the effect on Mouth Level Exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette.	YES	Yes	YES	Switching Study	24 h Urine	clinic	confi
74	2011	Research Article	Regul Toxicol Pharmacol.	Germany	Shepperd CJ, Eldridge AC, Errington G, Dixon M.	Industry BAT	Tobacco	A study to evaluate the effect on Mouth Level Exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette.	YES	Yes	YES	Switching Study	24 h Urine	clinic	confi
74	2011	Research Article	Regul Toxicol Pharmacol.	Germany	Shepperd CJ, Eldridge AC, Errington G, Dixon M.	Industry BAT	Tobacco	A study to evaluate the effect on Mouth Level Exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette.	YES	Yes	YES	Switching Study	24 h Urine	clinic	confi
74	2011	Research Article	Regul Toxicol Pharmacol.	Germany	Shepperd CJ, Eldridge AC, Errington G, Dixon M.	Industry BAT	Tobacco	A study to evaluate the effect on Mouth Level Exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette.	YES	Yes	YES	Switching Study	24 h Urine	clinic	confi
74	2011	Research Article	Regul Toxicol Pharmacol.	Germany	Shepperd CJ, Eldridge AC, Errington G, Dixon M.	Industry BAT	Tobacco	A study to evaluate the effect on Mouth Level Exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette.	YES	Yes	YES	Switching Study	24 h Urine	clinic	confi
74	2011	Research Article	Regul Toxicol Pharmacol.	Germany	Shepperd CJ, Eldridge AC, Errington G, Dixon M.	Industry BAT	Tobacco	A study to evaluate the effect on Mouth Level Exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette.	YES	Yes	YES	Switching Study	24 h Urine	clinic	confi

		Article	Pharmacol.		Errington G, Dixon M.			or cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette.				Study			cont
74	2011	Research Article	Regul Toxicol Pharmacol.	Germany	Shepperd CJ, Eldridge AC, Errington G, Dixon M.	Industry BAT	Tobacco	A study to evaluate the effect on Mouth Level Exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette.	YES	Yes	YES	Switching Study	24 h Urine	clinic confi	
74	2011	Research Article	Regul Toxicol Pharmacol.	Germany	Shepperd CJ, Eldridge AC, Errington G, Dixon M.	Industry BAT	Tobacco	A study to evaluate the effect on Mouth Level Exposure and biomarkers of exposure estimates of cigarette smoke exposure following a forced switch to a lower ISO tar yield cigarette.	YES	Yes	YES	Switching Study	24 h Urine	clinic confi	
9	2011	Research article	Nicotine Tob Res.	USA	Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P.	Academia UCSF	Other	Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.	YES	Yes	YES	Lab-based	Single measure	Not r	
9	2011	Research article	Nicotine Tob Res.	USA	Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P.	Academia UCSF	Other	Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.	YES	Yes	YES	Lab-based	Single measure	Not r	
9	2011	Research article	Nicotine Tob Res.	USA	Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P.	Academia UCSF	Other	Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.	YES	Yes	YES	Lab-based	Single measure	Not r	
9	2011	Research article	Nicotine Tob Res.	USA	Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P.	Academia UCSF	Other	Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.	YES	Yes	YES	Lab-based	Single measure	Not r	
9	2011	Research article	Nicotine Tob Res.	USA	Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P.	Academia UCSF	Other	Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.	YES	Yes	YES	Lab-based	Single measure	Not r	
9	2011	Research article	Nicotine Tob Res.	USA	Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P.	Academia UCSF	Other	Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.	YES	Yes	YES	Lab-based	Single measure	Not r	
9	2011	Research article	Nicotine Tob Res.	USA	Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P.	Academia UCSF	Other	Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.	YES	Yes	YES	Lab-based	Single measure	Not r	
9	2011	Research article	Nicotine Tob Res.	USA	Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P.	Academia UCSF	Other	Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure.	YES	Yes	YES	Lab-based	Single measure	Not r	
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure.	YES	Yes	YES	Switching Study	24 h urine	Com obse confi	
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure.	YES	Yes	YES	Switching Study	24 h urine	Com obse confi	
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and	YES	Yes	YES	Switching Study	24 h urine	Com obse confi	

								biomarkers of exposure.								
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure.	YES	Yes	YES	Switching Study		24 h urine	Com	obse confi
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure.	YES	Yes	YES	Switching Study		24 h urine	Com	obse confi
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure.	YES	Yes	YES	Switching Study		24 h urine	Com	obse confi
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure.	YES	Yes	YES	Switching Study		24 h urine	Com	obse confi
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure.	YES	Yes	YES	Switching Study		24 h urine	Com	obse confi
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure.	YES	Yes	YES	Switching Study		24 h urine	Com	obse confi
54	2011	Research article	Regul Toxicol Pharmacol.	Canada	Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R.	Industry, Imperial Tobacco	Tobacco	Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure.	YES	Yes	YES	Switching Study		24 h urine	Com	obse confi
79	2011	Research article	Cancer Epidemiol. Biomarkers Prev. 20, 234–238.	USA	Strasser, A.A., Benowitz, N.L., Pinto, A.G., Tang, K.Z., Hecht, S.S., Carmella, S.G., Tyndale, R.F., Lerman, C.E.,		Other	Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.	YES	Yes	YES	Cross-sectional study of cigarette smokers		Single measure 30-mL		
8	2010a	Research article	Cancer Epidemiol. Biomarkers Prev.	USA	Benowitz NL, Dains KM, Dempsey D, Havel C, Wilson M, Jacob P 3rd.	Academia UCSF	Other	Urine menthol as a biomarker of mentholated cigarette smoking.	YES	Yes	YES	Lab-based		Single measure	Not r	
8	2010a	Research article	Cancer Epidemiol. Biomarkers Prev.	USA	Benowitz NL, Dains KM, Dempsey D, Havel C, Wilson M, Jacob P 3rd.	Academia UCSF	Other	Urine menthol as a biomarker of mentholated cigarette smoking.	YES	Yes	YES	Lab-based		Single measure	Not r	
7	2010b	Research article	Cancer Epidemiol. Biomarkers Prev. 19, 2795–2800.	USA	Benowitz, N., Goniewicz, M.L., Eisner, Lazcano-Ponce, E., Zielinska-Danch, W., Koszowski, B., Sobczak, A., Havel, C., Jacob III, P.	Academia UCSF	Other	Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers.	YES	Yes	YES	Cross-sectional study of regular and occasional cigarette smokers from San Francisco, California				
7	2010b	Research article	Cancer Epidemiol. Biomarkers Prev. 19, 2795–2800.	USA	Benowitz, N., Goniewicz, M.L., Eisner, Lazcano-Ponce, E., Zielinska-Danch, W., Koszowski, B., Sobczak, A., Havel, C., Jacob III, P.	Academia UCSF	Other	Urine cotinine underestimates exposure to the tobacco-derived lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in passive compared with active smokers.	YES	Yes	YES	Cross-sectional study of regular and occasional cigarette smokers from Pittsburg, PA				
				Canada	Ashley DL, O'Connor RJ, Bernert JT, Watson CH, Polzin GM, Jain RB,			Effect of differing levels of tobacco-								

5	2010	Research Article	Cancer Epidemiol Biomarkers Prev.	Canada, United States, Australia, United Kingdom	Hammond D, Hatsukami DK, Giovino GA, Cummings KM, McNeill A, Shahab L, King B, Fong GT, Zhang L, Xia Y, Yan X, McCraw JM.	CDC and Academia	Other	specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers.	YES	Yes	YES	Lab-based		24-hour study period	Subj from failed protc
5	2010	Research Article	Cancer Epidemiol Biomarkers Prev.	Canada, United States, Australia, United Kingdom	Ashley DL, O'Connor RJ, Bernert JT, Watson CH, Polzin GM, Jain RB, Hammond D, Hatsukami DK, Giovino GA, Cummings KM, McNeill A, Shahab L, King B, Fong GT, Zhang L, Xia Y, Yan X, McCraw JM.	CDC and Academia	Other	Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers.	YES	Yes	YES	Lab-based		24-hour study period	Subj from failed protc
5	2010	Research Article	Cancer Epidemiol Biomarkers Prev.	Canada, United States, Australia, United Kingdom	Ashley DL, O'Connor RJ, Bernert JT, Watson CH, Polzin GM, Jain RB, Hammond D, Hatsukami DK, Giovino GA, Cummings KM, McNeill A, Shahab L, King B, Fong GT, Zhang L, Xia Y, Yan X, McCraw JM.	CDC and Academia	Other	Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers.	YES	Yes	YES	Lab-based		24-hour study period	Subj from failed protc
5	2010	Research Article	Cancer Epidemiol Biomarkers Prev.	Canada, United States, Australia, United Kingdom	Ashley DL, O'Connor RJ, Bernert JT, Watson CH, Polzin GM, Jain RB, Hammond D, Hatsukami DK, Giovino GA, Cummings KM, McNeill A, Shahab L, King B, Fong GT, Zhang L, Xia Y, Yan X, McCraw JM.	CDC and Academia	Other	Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers.	YES	Yes	YES	Lab-based		24-hour study period	Subj from failed protc
5	2010	Research Article	Cancer Epidemiol Biomarkers Prev.	Canada, United States, Australia, United Kingdom	Ashley DL, O'Connor RJ, Bernert JT, Watson CH, Polzin GM, Jain RB, Hammond D, Hatsukami DK, Giovino GA, Cummings KM, McNeill A, Shahab L, King B, Fong GT, Zhang L, Xia Y, Yan X, McCraw JM.	CDC and Academia	Other	Effect of differing levels of tobacco-specific nitrosamines in cigarette smoke on the levels of biomarkers in smokers.	YES	Yes	YES	Lab-based		24-hour study period	Subj from failed protc
17	2010	Research article	Biomarkers 15, 345–352.	USA	Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS.		Other	Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers.	YES	Yes	YES	Cross-sectional study of cigarette smokers	not randomized	spot	
17	2010	Research article	Biomarkers 15, 345–352.	USA	Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS.		Other	Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers.	YES	Yes	YES	Cross-sectional study of cigarette smokers	not randomized	spot	
17	2010	Research article	Biomarkers 15, 345–352.	USA	Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS.		Other	Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers.	YES	Yes	YES	Cross-sectional study of cigarette smokers	not randomized	spot	
17	2010	Research article	Biomarkers 15, 345–352.	USA	Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS.		Other	Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers.	YES	Yes	YES	Cross-sectional study of cigarette smokers	not randomized	spot	
17	2010	Research article	Biomarkers 15, 345–352.	USA	Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS.		Other	Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers.	YES	Yes	YES	Cross-sectional study of cigarette smokers	not randomized	spot	

17	2010	Research article	Biomarkers 15, 345–352.	USA	Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS.		Other	Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers.	YES	Yes	YES	Cross-sectional study of cigarette smokers	not randomized	spot	
17	2010	Research article	Biomarkers 15, 345–352.	USA	Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS.		Other	Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers.	YES	Yes	YES	Cross-sectional study of cigarette smokers	not randomized	spot	
17	2010	Research article	Biomarkers 15, 345–352.	USA	Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS.		Other	Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers.	YES	Yes	YES	Cross-sectional study of cigarette smokers	not randomized	spot	
17	2010	Research article	Biomarkers 15, 345–352.	USA	Church TR, Anderson KE, Le C, Zhang Y, Kampa DM, Benoit AR, Yoder AR, Carmella SG, Hecht SS.		Other	Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers.	YES	Yes	YES	Cross-sectional study of cigarette smokers	not randomized	spot	
29	2010		Addiction 105, 343–355.	USA	Hatsukami, D.K., Kotlyar, M., Hertsgaard, L.A., Zhang, Y., Carmella, S.G., Jensen, J.A., Allen, S.S., Shields, P.G., Murphy, S.E., Stepanov, I., Hecht, S.S.	U of Minnesota Tob Use Res Ctr	Other	Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation.	YES	Yes	YES	Baseline data from cigarette smokers before switching to 0.3 mg FTC nicotine cigarettes	Randomized, parallel arm, semi-blinded study		
29	2010		Addiction 105, 343–355.	USA	Hatsukami, D.K., Kotlyar, M., Hertsgaard, L.A., Zhang, Y., Carmella, S.G., Jensen, J.A., Allen, S.S., Shields, P.G., Murphy, S.E., Stepanov, I., Hecht, S.S.	U of Minnesota Tob Use Res Ctr	Other	Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation.	YES	Yes	YES	Baseline data from cigarette smokers before switching to 0.3 mg FTC nicotine cigarettes	Randomized, parallel arm, semi-blinded study		
29	2010		Addiction 105, 343–355.	USA	Hatsukami, D.K., Kotlyar, M., Hertsgaard, L.A., Zhang, Y., Carmella, S.G., Jensen, J.A., Allen, S.S., Shields, P.G., Murphy, S.E., Stepanov, I., Hecht, S.S.	U of Minnesota Tob Use Res Ctr	Other	Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation.	YES	Yes	YES	Baseline data from cigarette smokers before switching to 0.3 mg FTC nicotine cigarettes	Randomized, parallel arm, semi-blinded study		
22	2009	Research Article	Int J Cancer. 2009	USA	Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.	Universities of Hawaii and Minnesota	Other	Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.	YES	Yes	YES	In-home interviews with urine collection	12 h (overnight) urine		Parti exclt on fe CPD nega
22	2009	Research Article	Int J Cancer. 2009	USA	Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.	Universities of Hawaii and Minnesota	Other	Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.	YES	Yes	YES	In-home interviews with urine collection	12 h (overnight) urine		Parti exclt on fe CPD nega
22	2009	Research Article	Int J Cancer. 2009	USA	Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.	Universities of Hawaii and Minnesota	Other	Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.	YES	Yes	YES	In-home interviews with urine collection	12 h (overnight) urine		Parti exclt on fe CPD nega
22	2009	Research Article	Int J Cancer. 2009	USA	Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.	Universities of Hawaii and Minnesota	Other	Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.	YES	Yes	YES	In-home interviews with urine collection	12 h (overnight) urine		Parti exclt on fe CPD nega

22	2009	Research Article	Int J Cancer. 2009	USA	Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.	Universities of Hawaii and Minnesota	Other	Carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.	YES	Yes	YES	In-home interviews with urine collection		12 h (overnight) urine	Parti exclt on fe CPD nega
22	2009	Research Article	Int J Cancer. 2009	USA	Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.	Universities of Hawaii and Minnesota	Other	Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.	YES	Yes	YES	In-home interviews with urine collection		12 h (overnight) urine	Parti exclt on fe CPD nega
22	2009	Research Article	Int J Cancer. 2009	USA	Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.	Universities of Hawaii and Minnesota	Other	Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.	YES	Yes	YES	In-home interviews with urine collection		12 h (overnight) urine	Parti exclt on fe CPD nega
22	2009	Research Article	Int J Cancer. 2009	USA	Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.	Universities of Hawaii and Minnesota	Other	Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.	YES	Yes	YES	In-home interviews with urine collection		12 h (overnight) urine	Parti exclt on fe CPD nega
22	2009	Research Article	Int J Cancer. 2009	USA	Derby KS, Cuthrell K, Caberto C, Carmella S, Murphy SE, Hecht SS, Le Marchand L.	Universities of Hawaii and Minnesota	Other	Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.	YES	Yes	YES	In-home interviews with urine collection		12 h (overnight) urine	Parti exclt on fe CPD nega
75	2009	Research article	Regul Toxicol Pharmacol	Germany	Shepperd CJ, Eldridge AC, Mariner DC, McEwan M, Errington G, Dixon M.		Other	A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure.	yes	yes	YES	at-home and clinical stays, stratified by tar level	Not randomized	24 hour	24 h chec who non-cotin
75	2009	Research article	Regul Toxicol Pharmacol	Germany	Shepperd CJ, Eldridge AC, Mariner DC, McEwan M, Errington G, Dixon M.		Other	A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure.	yes	yes	YES	at-home and clinical stays, stratified by tar level	Not randomized	24 hour	24 h chec who non-cotin
75	2009	Research article	Regul Toxicol Pharmacol	Germany	Shepperd CJ, Eldridge AC, Mariner DC, McEwan M, Errington G, Dixon M.		Other	A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure.	yes	yes	YES	at-home and clinical stays, stratified by tar level	Not randomized	24 hour	24 h chec who non-cotin
75	2009	Research article	Regul Toxicol Pharmacol	Germany	Shepperd CJ, Eldridge AC, Mariner DC, McEwan M, Errington G, Dixon M.		Other	A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure.	yes	yes	YES	at-home and clinical stays, stratified by tar level	Not randomized	24 hour	24 h chec who non-cotin
53	2009	Research article	Regul Toxicol Pharmacol	USA	Mendes P, Liang Q, Frost-Pineda K, Munjal S, Walk RA, Roethig HJ.		Other	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US.	YES	yes	YES	cross-sectional, stratified by four tar yield groups	Not randomized	24 hour	creal plaus
53	2009	Research article	Regul Toxicol Pharmacol	USA	Mendes P, Liang Q, Frost-Pineda K, Munjal S, Walk RA, Roethig HJ.		Other	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US.	YES	yes	YES	cross-sectional, stratified by four tar yield groups	Not randomized	24 hour	creal plaus

53	2009	Research article	Regul Toxicol Pharmacol	USA	Mendes P, Liang Q, Frost-Pineda K, Munjal S, Walk RA, Roethig HJ.		Other	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US.	YES	yes	YES	cross-sectional, stratified by four tar yield groups	Not randomized	24 hour	crea
53	2009	Research article	Regul Toxicol Pharmacol	USA	Mendes P, Liang Q, Frost-Pineda K, Munjal S, Walk RA, Roethig HJ.		Other	The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US.	YES	yes	YES	cross-sectional, stratified by four tar yield groups	Not randomized	24 hour	crea
13	2009	Research article	Chem Res Toxicol 22(4): 734-741	USA	Carmella SG, Chen M, Han S, Briggs A, Jensen J, Hatsukami DK, Hecht SS.		Other	Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers.	YES	YES	YES	Clinical	Not randomized		
37	2009	Research article	Cancer Epidemiol. Biomarkers Prev. 18, 622–629.	USA	Heck JD.		Other	Smokers of menthol and nonmenthol cigarettes exhibit similar levels of biomarkers of smoke exposure.	YES	YES	YES	Cross sectional study of menthol cigarette smokers	Not randomized		
37	2009	Research article	Cancer Epidemiol. Biomarkers Prev. 18, 622–629.	USA	Heck JD.		Other	Smokers of menthol and nonmenthol cigarettes exhibit similar levels of biomarkers of smoke exposure.	YES	YES	YES	Cross sectional study of menthol cigarette smokers	Not randomized		
16	2009	Research article	Cancer Epidemiol. Biomarkers Prev.	USA	Church		Other	A prospectively measured	Yes	yes	YES	Case-control of lung cancer patients and control	random	prospective blood sample from PLCO study	
16	2009	Research article	Cancer Epidemiol. Biomarkers Prev.	USA	Church		Other		YES	Yes	YES	Case-control of lung cancer patients and control	random	prospective blood sample from PLCO study	
56	2009	Research article	Cancer Epidemiol Biomarkers Prev	USA	Muscat JE, Chen G, Kripe A, Stellman SD, Lazarus P, Richie JP Jr.		Other	Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation.	Yes	yes	YES	Cross-sectional study of menthol cigarette smokers	not randomized		Excl: takin antid med: liver funct
56	2009	Research article	Cancer Epidemiol Biomarkers Prev	USA	Muscat JE, Chen G, Kripe A, Stellman SD, Lazarus P, Richie JP Jr.		Other	Effects of menthol on tobacco smoke exposure, nicotine dependence, and NNAL glucuronidation.	YES	Yes	YES	Cross-sectional study of menthol cigarette smokers	not randomized		Excl: takin antid med: liver funct
26	2009	Research article	Cancer Epidemiol. Biomarkers Prev. 18, 3421–3425.	USA, Poland	Goniewicz, M.L., Havel, C.M., Peng, M.W., Jacob III, P., Dempsey, D., Yu, L., Zielinska-Danch, W., Koszowski, B., Czogala, J., Sobczak, A., Benowitz, N.L.		Other	Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.	Yes	Yes	YES	Hospitalized clinic in US and nonhospitalized in Poland	not randomized	24 hour	Excl: with NNA
26	2009	Research article	Cancer Epidemiol. Biomarkers Prev. 18, 3421–3425.	USA, Poland	Goniewicz, M.L., Havel, C.M., Peng, M.W., Jacob III, P., Dempsey, D., Yu, L., Zielinska-Danch, W., Koszowski, B., Czogala, J., Sobczak, A., Benowitz, N.L.		Other	Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.	Yes	Yes	YES	Hospitalized clinic in US and nonhospitalized in Poland	not randomized		Excl: with NNA
67	2008	Research article	Nicotine Tob Res. 2008	USA	Sarkar M, Kapur S, Frost-Pineda K, Feng S, Wang J, Liang Q, Roethig H.	Industry Philip Morris USA	Tobacco	Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies.	YES	Yes	YES	Four RCT, open-label switching. Two short term and two long term [Baseline data from cigarette smokers before switching to 6 mg FTC tar conventional cigarettes]			
67	2008	Research article	Nicotine Tob Res. 2008	USA	Sarkar M, Kapur S, Frost-Pineda K, Feng S, Wang J, Liang Q, Roethig H.	Industry Philip Morris USA	Tobacco	Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies.	YES	Yes	YES	Four RCT, open-label switching. Two short term and two long term			
								Evaluation of				Four RCT, open-label			

67	2008	Research article	Nicotine Tob Res. 2008	USA	Sarkar M, Kapur S, Frost-Pineda K, Feng S, Wang J, Liang Q, Roethig H.	Industry Philip Morris USA	Tobacco	biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies.	YES	Yes	YES	switching. Two short term and two long term [Baseline data from cigarette smokers before switching to 11 mg FTC tar conventional cigarettes]			
67	2008	Research article	Nicotine Tob Res. 2008	USA	Sarkar M, Kapur S, Frost-Pineda K, Feng S, Wang J, Liang Q, Roethig H.	Industry Philip Morris USA	Tobacco	Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies.	YES	Yes	YES	Four RCT, open-label switching. Two short term and two long term			
67	2008	Research article	Nicotine Tob Res. 2008	USA	Sarkar M, Kapur S, Frost-Pineda K, Feng S, Wang J, Liang Q, Roethig H.	Industry Philip Morris USA	Tobacco	Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies.	YES	Yes	YES	Four RCT, open-label switching. Two short term and two long term [Baseline data from cigarette smokers before switching to 6 mg FTC tar charcoal cigarettes]			
67	2008	Research article	Nicotine Tob Res. 2008	USA	Sarkar M, Kapur S, Frost-Pineda K, Feng S, Wang J, Liang Q, Roethig H.	Industry Philip Morris USA	Tobacco	Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies.	YES	Yes	YES	Four RCT, open-label switching. Two short term and two long term [Baseline data from cigarette smokers before switching to 11 mg FTC tar charcoal cigarettes]			
43	2008	Research article	Cancer Research	USA	LeMarchand L, Derby KS, Murphy SE, Hecht SS, Hatsukami D, Carmella SG, Tirikaine M, and Wang H.	University of Hawaii	Other	Smokers with the CHRNA Lung Cancer-Associated Variants Are Exposed to Higher Levels of Nicotine Equivalents and a Carcinogenic Tobacco-Specific Nitrosamine	YES	Yes	YES	A multiethnic cohort study to test whether two linked lung cancer risk variants in CHRNA3 (rs1051730) and CHRNA5 (rs16969968) are associated with intensity of smoking and exposure to a tobacco-specific carcinogenic nitrosamine per cigarette dose.	Random		